var title_f24_1_24592="Deformity from Type III AC joint injury";
var content_f24_1_24592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Deformity following acute Type III AC joint injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 65-year-old masters cyclist and professional trombone player reports full, pain-free function after AC injury suffered when a dog ran out in front of him while cycling. Note the intact trapezius and anterior deltoid insertion on the clavicle, and drooped shoulder rather than elevated clavicle in the chronic state.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24592=[""].join("\n");
var outline_f24_1_24592=null;
var title_f24_1_24593="IVUS image coronary artery";
var content_f24_1_24593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracoronary ultrasound image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The intracoronary image of the artery shows the different layers of the arterial wall including the intima (I), media (M) and adventitia (A). The corresponding histology of these layers is also shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neil Weissman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24593=[""].join("\n");
var outline_f24_1_24593=null;
var title_f24_1_24594="Patient information: Lymphedema after breast cancer treatment (The Basics)";
var content_f24_1_24594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17203\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/2/40997\">",
"         Lymphatic system in women",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/19/2357\">",
"         Patient information: Breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/8/8321\">",
"         Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/32/15876\">",
"         Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lymphedema after breast cancer treatment (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/lymphedema-after-breast-cancer-treatment-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6663106\">",
"      <span class=\"h1\">",
"       What is lymphedema?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lymphedema is a buildup of fluid in the hand or arm. It happens in some women who have had surgery or radiation treatment for breast cancer. Not all women treated for breast cancer get lymphedema. &nbsp;",
"     </p>",
"     <p>",
"      The body has a network of vessels called the called the &ldquo;lymphatic system&rdquo; that carries a clear fluid called &ldquo;lymph&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef86801 \" href=\"UTD.htm?40/2/40997\">",
"       figure 1",
"      </a>",
"      ). The lymphatic system is similar to the system of blood vessels. But instead of blood, the lymphatic system carries lymph, which contains infection-fighting cells. Lymphedema happens when the flow of lymph through the lymphatic system gets backed up. This can happen after cancer treatment, and can be a common problem in patients treated for breast cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663121\">",
"      <span class=\"h1\">",
"       What are the symptoms of lymphedema?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms of lymphedema are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling in your fingers, hand, or arm",
"       </li>",
"       <li>",
"        Aching pain",
"       </li>",
"       <li>",
"        Tight or heavy feeling in your arm",
"       </li>",
"       <li>",
"        Trouble moving your arm",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The symptoms can come on slowly. It might be weeks, months, or even years after your cancer treatment before you have symptoms of lymphedema.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663138\">",
"      <span class=\"h1\">",
"       Is there a test for lymphedema?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no test. Your doctor or nurse can figure out if you have lymphedema by talking to you about your symptoms and doing an exam. An important part of the exam will be to measure the length around your arm (called your arm circumference).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663153\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It is very important to avoid injury or infections of your affected arm. There are also actions you can take to help prevent more swelling.",
"     </p>",
"     <p>",
"      To avoid injury:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Keep your skin clean. Wash with a mild soap every day.",
"       </li>",
"       <li>",
"        Be careful with your nails. Don&rsquo;t pick at the skin around your nails or cut your cuticles.",
"       </li>",
"       <li>",
"        Use lotion to keep your skin from getting dry and cracked.",
"       </li>",
"       <li>",
"        Use an electric razor instead of a manual razor to shave under your arms.",
"       </li>",
"       <li>",
"        Always use sunscreen when you go outside.",
"       </li>",
"       <li>",
"        Wear gloves when gardening, cooking, or doing other things that could hurt your skin.",
"       </li>",
"       <li>",
"        If you do get a small cut, scrape, or bite on your arm or hand, clean it well with soap and water. Then use an antibiotic cream, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?1/56/1925?source=see_link\">",
"         bacitracin",
"        </a>",
"        . Call your doctor or nurse if it does not heal quickly or if you have signs of an infection.",
"       </li>",
"       <li>",
"        Do",
"        <strong>",
"         not",
"        </strong>",
"        have shots, blood draws, IV lines, or acupuncture in your affected arm.",
"       </li>",
"       <li>",
"        Avoid having your blood pressure taken on your affected arm.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To prevent swelling:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear loose fitting clothes and jewelry. You don&rsquo;t want to wear anything tight on your affected hand or arm, unless it is a special garment or bandage your doctor or nurse gives you.",
"       </li>",
"       <li>",
"        If you use a purse, carry it on your non-affected arm.",
"       </li>",
"       <li>",
"        Avoid saunas, steam baths, and hot tubs. Heat can cause more swelling.",
"       </li>",
"       <li>",
"        Keep your weight under control. Being too heavy can make your lymphedema worse.",
"       </li>",
"       <li>",
"        Do not let your arm hang at your side for long periods of time (more than 15 minutes) without moving it.",
"       </li>",
"       <li>",
"        Keep your arm raised on pillows when you&rsquo;re sitting down.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663168\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should call your doctor or nurse if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Increased swelling of your hand or arm",
"       </li>",
"       <li>",
"        Redness or a rash on your arm",
"       </li>",
"       <li>",
"        Your arm feels warm to the touch",
"       </li>",
"       <li>",
"        You have a fever higher than 100.4&deg;F (38&deg;C) that is not due to a cold or other illness",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663183\">",
"      <span class=\"h1\">",
"       How is lymphedema treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no cure for lymphedema. But there are treatments that can help reduce the swelling and make you more comfortable. These treatments work best if you start them early, so see a doctor or nurse as soon as you notice any swelling. It is best to go to clinics that have people who have experience treating lymphedema.",
"     </p>",
"     <p>",
"      Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Exercise &ndash; Doctors used to think that people with lymphedema needed to avoid exercising the affected arm. Now research shows that exercise can actually help with the condition. During exercise, people with lymphedema should always wear a compression bandage or sleeve (see below). &nbsp;",
"       </li>",
"       <li>",
"        Compression bandaging &ndash; Compression bandaging is a special kind of bandaging that puts gentle, steady pressure on the swollen area. This helps keep the swelling down. &nbsp; &nbsp;",
"       </li>",
"       <li>",
"        Compression &ldquo;sleeves&rdquo; &ndash; Compression sleeves work a lot like compression bandaging. They put gentle, steady pressure on the affected arm to keep swelling down. &nbsp; &nbsp;",
"       </li>",
"       <li>",
"        Manual lymphatic drainage &ndash; For this treatment, a physical therapist massages your arm in a special way to help move the fluid that has built up.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663198\">",
"      <span class=\"h1\">",
"       Can lymphedema be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lymphedema cannot always be prevented, but if you treat it early, you might be able to keep it from becoming too severe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663230\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"       Patient information: Breast cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=see_link\">",
"       Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"       Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/1/24594?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17203 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24594=[""].join("\n");
var outline_f24_1_24594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663106\">",
"      What is lymphedema?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663121\">",
"      What are the symptoms of lymphedema?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663138\">",
"      Is there a test for lymphedema?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663153\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663168\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663183\">",
"      How is lymphedema treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663198\">",
"      Can lymphedema be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663230\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/2/40997\">",
"      Lymphatic system in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=related_link\">",
"      Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=related_link\">",
"      Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_1_24595="Flavocoxid (plant flavonoids and zinc): Drug information";
var content_f24_1_24595=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flavocoxid (plant flavonoids and zinc): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/34/4644?source=see_link\">",
"    see \"Flavocoxid (plant flavonoids and zinc): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F729844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Limbrel 250&trade;;",
"     </li>",
"     <li>",
"      Limbrel 500&trade;;",
"     </li>",
"     <li>",
"      Limbrel&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F729847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-inflammatory Agent;",
"     </li>",
"     <li>",
"      Nutritional Supplement",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F729870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Management of osteoarthritis:",
"     </b>",
"     Oral: 250-500 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F729873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Limbrel&trade;: 250 mg [DSC], 500 mg [DSC] [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [new formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Limbrel 250&trade;: 250 mg [gluten free, sucrose free; contains elemental zinc 10 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Limbrel 500&trade;: 500 mg [gluten free, sucrose free; contains elemental zinc 10 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6131724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9549679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Administer with or without meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F729848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Clinical dietary management of the metabolic processes of osteoarthritis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F729856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &ge;2%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, varicose veins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Psoriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Occult stools (statistically similar to placebo)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fluid on the knee",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Jaundice, liver injury",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F729851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to flavocoxid, flavonoids, or any component of the formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F729852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disorders; may cause gastrointestinal bleeding or ulceration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NSAIDs: Avoid concomitant use with NSAIDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: Should only be used under the close supervision of a healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F729860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F729859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F729849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Flavocoxid has not been studied in pregnant women; use during pregnancy is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F729850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16570844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Flavocoxid has not been studied in nursing women; breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Limbrel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (60): $115.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $124.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Limbrel250 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-50 mg (60): $115.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Limbrel500 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-50 mg (60): $124.69",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F729864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Exerts anti-inflammatory properties through nonspecific inhibition of cyclooxygenase (COX) and lipoxygenase (5-LOX) pathways; may also possess general analgesic and antioxidant/anticytokine properties",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F729866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Metabolism: Primarily via glucuronidation and sulfation",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chalasani N, Vuppalanchi R, Navarro V, \"Acute Liver Injury Due to Flavocoxid (Limbrel), a Medical Food for Osteoarthritis: A Case Series,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(12):857-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24595/abstract-text/22711078/pubmed\" id=\"22711078\" target=\"_blank\">",
"        22711078",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9006 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24595=[""].join("\n");
var outline_f24_1_24595=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729844\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729847\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729870\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062880\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881433\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881434\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729873\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6131724\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9549679\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729848\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729856\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729851\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729852\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729860\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729859\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729849\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729850\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570844\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422287\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729864\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729866\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9006\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9006|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/34/4644?source=related_link\">",
"      Flavocoxid (plant flavonoids and zinc): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_1_24596="Contact dermatitis allergic 1";
var content_f24_1_24596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Discrete and confluent red, scaly, weepy, crusted papules and plaques. A 25-year-old woman consulted a dermatologist for an acute eczematous dermatitis on her head, neck and shoulders. The eruption appeared five days after she had black hair dye applied to her hair at the hairdresser. Patch tests were positive for para-phenylenediamine. Para-phenylenediamine is a dark dye used in almost all permanent hair dyes and some semi-permanent hair coloring. It is a potent allergen which triggers severe acute contact dermatitis in sensitized individuals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Eric Ehrsam, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24596=[""].join("\n");
var outline_f24_1_24596=null;
var title_f24_1_24597="Endoscopic ultrasound: Anatomy of the normal esophagus";
var content_f24_1_24597=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic ultrasound: Anatomy of the normal esophagus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/1/24597/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24597/contributors\">",
"     Frank G Gress, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/1/24597/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24597/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/1/24597/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24597/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/1/24597/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) is an endoscopic technique that provides highly accurate imaging of mucosal, submucosal, and periluminal structures. It is often used for the preoperative staging of gastrointestinal (GI) malignancies such as esophageal, gastric, pancreatic and rectal cancers for which it has an accuracy of 90, 88, and 90 percent, respectively, when performed with experienced hands [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24597/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EUS provides high resolution imaging of the GI tract by its unique ability to differentiate the histologic layers of the GI tract wall [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24597/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. The most commonly used echoendoscopes operate across a broad range of frequencies ranging from 5 to 20 MHz, with a variable depth of penetration and resolution. These echoendoscopes produce an image of the GI tract wall consisting of five sections or layers. A discussion of high frequency EUS with ranges &gt;20 MHz revealing a nine layer GI tract wall is covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35509?source=see_link\">",
"     \"High frequency catheter endoscopic ultrasonography\"",
"    </a>",
"    .) These layers correspond to the five distinct histologic layers of the gut wall:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The innermost, medial layer (lumen) is known as the superficial mucosal layer",
"     </li>",
"     <li>",
"      The second layer corresponds to the lamina propria or deep mucosa",
"     </li>",
"     <li>",
"      The third layer is known as the submucosa",
"     </li>",
"     <li>",
"      The fourth layer is referred to as the muscularis propria",
"     </li>",
"     <li>",
"      The fifth layer is known as the adventitia in the esophagus and serosa in the stomach, duodenum, and rectum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Visually, these endosonographic layers appear as five alternating hyperechoic and hypoechoic bands (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73301 \" href=\"UTD.htm?37/9/38035\">",
"     image 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The innermost layer (lumen) is hyperechoic or echogenic, and is attributed to the initial echo-interface between the ultrasound waves, the GI tract mucosa, and surrounding fluid",
"     </li>",
"     <li>",
"      The second layer is a hypoechoic or dark band that corresponds to the actual mucosa and deep mucosa",
"     </li>",
"     <li>",
"      The third layer is a hyperechoic or bright echo that corresponds to the submucosa",
"     </li>",
"     <li>",
"      The fourth layer represents the muscularis propria and is depicted as a hypoechoic or dark band",
"     </li>",
"     <li>",
"      The fifth layer, which is seen as a hyperechoic or bright echogenic band, is considered the serosa in the stomach, duodenum, and rectum and the adventitia in the esophagus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cross-sectional anatomy of the GI tract wall seen on EUS corresponds clinically to the tumor, nodal, and metastasis (TNM) staging classification system currently used to stage the majority of GI tumors. Therefore, EUS has great value in staging GI luminal based tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the EUS anatomy of the esophagus. The role of EUS in the diagnosis and treatment of esophageal lesions is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1242?source=see_link\">",
"     \"Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4281?source=see_link\">",
"     \"Therapeutic endoscopic ultrasound\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination of the esophagus is one of the easiest EUS procedures to perform, second only to the rectum, since the esophagus is essentially a straight tube requiring little to no manipulation of the echoendoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24597/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. EUS examination resembles standard endoscopy of the upper gastrointestinal tract. The operator performs the procedure with the patient in a left lateral decubitus position. Echoendoscopes are usually side-viewing and have an ultrasound transducer located at the tip that emits high frequency acoustic waves to the surrounding tissues. The latter permits the acquisition of unique \"real-time\" views of the gut wall and the surrounding organs and blood vessels.",
"   </p>",
"   <p>",
"    \"Linear\" instruments scan in the same plane as the long axis of the endoscope, whereas mechanical \"radial\" instruments have a rotating mechanical ultrasound probe that scans in a circle at 90&deg; to the long axis of the endoscope. The ultrasound signal is then integrated by a complex processor and transmitted in real-time to a video screen. Linear instruments are used for EUS-guided fine needle aspiration. This discussion will focus on the anatomical relationships that can be imaged from the esophagus using radial scanning endosonography since most centers with EUS use the radial scanning echoendoscope for GI tumor staging.",
"   </p>",
"   <p>",
"    The image obtained with radial EUS is similar to that of a computed tomographic (CT) scan. As a general rule, the upper part of the screen is anterior, and the right part of the screen is to the patient's left side. EUS depends upon a thorough knowledge of the spatial anatomy of the mediastinum relative to the esophagus. This understanding of the anatomy gives the endoscopist the ability to adapt to the many positions or views that can be obtained with the echoendoscope. Furthermore, the anatomic relationships must be retained and integrated for both radial and linear EUS imaging, making EUS a difficult procedure to learn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17495045\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the radial scanning echoendoscope is introduced into the esophagus, it should be advanced slowly into the stomach just past the gastroesophageal junction, which is usually approximately 40 to 45 cm from the incisors. When EUS scanning is initiated, the aorta should be readily seen as an oval shaped, approximately 2 cm hypoechoic structure, positioned between five and six o'clock. If it is not seen, gentle advancement or withdrawal of the instrument will usually bring it into view. The image can be adjusted by rotating the echoendoscope (either manually or electronically) until the aorta is in the five to six o'clock position.",
"   </p>",
"   <p>",
"    The aorta can then be traced to the celiac axis, an important anatomical area that needs evaluation for the presence of lymph node metastasis during tumor staging. Positive celiac lymph nodes are an ominous sign since they typically represent M1 or distant metastasis, usually precluding an attempt at curative resection. In most cases, the celiac trunk can be visualized. The hepatic artery can be seen coursing to the right and superiorly and the splenic artery can be seen coursing to the left. The vascular structures are easily recognized by the experienced endosonographer; however, the novice can take advantage of the Doppler and color flow capability on the linear equipment to visualize these structures. Another benefit of",
"    <span class=\"nowrap\">",
"     Doppler/color",
"    </span>",
"    flow is to identify small intramural vessels that might interfere with the safe performance of EUS-guided fine needle aspiration biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Distal esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five-layer wall pattern of the esophagus comes into view as the echoendoscope is slowly withdrawn cephalad (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73301 \" href=\"UTD.htm?37/9/38035\">",
"     image 1",
"    </a>",
"    ). The normal wall thickness of the esophagus measures 3 to 4 mm. Overinflation of the balloon should be avoided since it can cause imaging artifacts and flatten the wall, making it difficult to clearly discern the five layers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24597/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. In addition, air that is not completely suctioned from the lumen will create artifact, making imaging difficult.",
"   </p>",
"   <p>",
"    The major anatomical landmarks in the distal esophagus are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The aorta, which as previously stated, is located in the five to six o'clock positions.",
"     </li>",
"     <li>",
"      The spine, which will be visualized in the seven o'clock position, just adjacent to the aorta.",
"     </li>",
"     <li>",
"      The left lobe of the liver, which is seen between the 6 and 12 o'clock positions. The inferior vena cava and other hepatic structures (ie, hepatic veins and bile ducts) will be frequently noted coursing through this portion of the liver.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the distal esophagus, multiple wall layers can sometimes be appreciated in patients with a hiatal hernia. This probably occurs as a result of simultaneous imaging of the hiatal hernia and cardia of the stomach. More accurate imaging of this area and the distal esophageal wall can be achieved by instilling small amounts of water into this region, which can help open up the folds within the hiatal hernia.",
"   </p>",
"   <p>",
"    During withdrawal of the echoendoscope, the heart, specifically the left atrium, will begin to come into view in the twelve o'clock position. Upon further interrogation of this area, the left pulmonary artery can be seen as it heads posteriorly to the left of the ascending aorta, and the pulmonary veins can be seen entering the left atrium. The mitral valve leaflets can sometimes be imaged; the valves are seen opening from the left atrium into the left ventricle. The left ventricle, right atrium, and right ventricle are more difficult to image and may not be seen distinctly in all cases since they are situated posterior to the left atrium.",
"   </p>",
"   <p>",
"    As the echoendoscope is further withdrawn, small pericardial effusions may be seen below the heart. At this point, the left lung will begin to appear at the two o'clock position while the right lung can be seen in the nine o'clock location. The lungs have a unique EUS image of hyperechoic rings that represents air within the lung parenchyma. Further withdrawal of the instrument will begin imaging structures surrounding the mid-esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mid-esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major anatomical landmarks of the mid-esophagus include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The aorta again located at the five to six o'clock positions, which then evolves into the aortic arch",
"     </li>",
"     <li>",
"      The spine at the seven o'clock position",
"     </li>",
"     <li>",
"      The azygous vein at the eight o'clock position",
"     </li>",
"     <li>",
"      The thoracic duct",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Keeping the aorta in the five to six o'clock position, the spine will remain visualized at the seven o'clock position. The azygous vein will be seen to the right of the aorta and will move anterior to the spine and upwards along the right lung. The thoracic duct will be occasionally seen as a small, round anechoic dot to the left of the aorta. As the scope is withdrawn further, the azygous vein will be seen moving forward and merging into the superior vena cava. The aortic arch will be noted on the left as it arises from the aorta and can be seen curving towards the right. Also, the left and right bronchi can be seen as small hyperechoic rings that represent cartilage and air, at the one o'clock and eleven o'clock positions, respectively.",
"   </p>",
"   <p>",
"    As the echoendoscope is withdrawn, the left and right bronchi can be observed forming the trachea at the level of the hilum, which is usually about 26 to 28 cm from the incisors. Just below this region lies the subcarina where one can frequently encounter benign mediastinal lymph nodes. These lymph nodes characteristically appear as hyperechoic structures with indistinct margins and irregular shapes (ie, oblong, rectangular, and triangular). In cases of malignant nodes, more distinct and sharper borders and a round shape are typical. Benign lymph nodes are usually less than 1 cm in size. However, these nodes can be enlarged in patients with previous mediastinal infections, such as histoplasmosis, or even sarcoid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Proximal esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal or cervical esophagus is entered upon further withdrawal of the instrument. In this position, the blood vessels of the neck come into view, while the aortic arch falls below the imaging plane. The subclavian artery can be seen posteriorly while the left common carotid artery and sometimes the brachiocephalic trunk are seen anteriorly.",
"   </p>",
"   <p>",
"    The location of the trachea in the mid-plane causes artifacts arising from the trachea itself, and from air within its lumen, which can hamper imaging at this station. In some patients, the thyroid gland can be seen, appearing as a hypoechoic structure in the center of the image. Less commonly, the thymus gland, which lies distal to the thyroid near the clavicle, can be seen.",
"   </p>",
"   <p>",
"    As the instrument is further withdrawn to near the upper esophageal sphincter (approximately 18 to 20 cm), the patient will become uncomfortable and imaging will be difficult, as a result of patient intolerance and air artifact from the trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24597/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. However, in some patients the carotid arteries and internal jugular veins can be imaged. At this point, the balloon should be deflated, the transducer should be stopped, and the scope gently removed from the patient's mouth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While EUS of the esophagus is generally safe, complications can occur from conscious sedation, therapeutic interventions or passage of the echoendoscope. The incidence of cervical esophageal perforation was 0.06 percent in a series of 4894 examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24597/abstract/16\">",
"     16",
"    </a>",
"    ]. All were recognized during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24597/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28310?source=see_link\">",
"     \"Complications of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17495194\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic ultrasound (EUS) is an endoscopic technique that provides highly accurate imaging of mucosal, submucosal, and periluminal structures. It is often used for the preoperative staging of gastrointestinal (GI) malignancies such as esophageal, gastric, pancreatic, and rectal cancers, for which it has accuracies of 90, 88, and 90 percent, respectively, when performed with experienced hands. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard echoendoscopes produce an image of the GI tract wall consisting of five sections or layers. Visually, these endosonographic layers appear as five alternating hyperechoic and hypoechoic bands (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73301 \" href=\"UTD.htm?37/9/38035\">",
"       image 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The innermost layer (lumen) is hyperechoic or echogenic and is attributed to the initial echo-interface between the ultrasound waves, the GI tract mucosa, and surrounding fluid",
"     </li>",
"     <li>",
"      The second layer is a hypoechoic or dark band that corresponds to the actual mucosa and deep mucosa",
"     </li>",
"     <li>",
"      The third layer is a hyperechoic or bright echo that corresponds to the submucosa",
"     </li>",
"     <li>",
"      The fourth layer represents the muscularis propria and is depicted as a hypoechoic or dark band",
"     </li>",
"     <li>",
"      The fifth layer, which is seen as a hyperechoic or bright echogenic band, is considered the serosa in the stomach, duodenum, and rectum and the adventitia in the esophagus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Structures that are visualized from the stomach include (see",
"      <a class=\"local\" href=\"#H17495045\">",
"       'Stomach'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The aorta",
"     </li>",
"     <li>",
"      The celiac axis and surrounding lymph nodes",
"     </li>",
"     <li>",
"      The celiac trunk",
"     </li>",
"     <li>",
"      The hepatic artery",
"     </li>",
"     <li>",
"      The splenic artery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Structures seen in the distal esophagus are (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Distal esophagus'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The aorta",
"     </li>",
"     <li>",
"      The spine",
"     </li>",
"     <li>",
"      The left lobe of the liver",
"     </li>",
"     <li>",
"      The inferior vena cava and hepatic structures (ie, hepatic veins and bile ducts) will be frequently noted coursing through the left lobe of the liver",
"     </li>",
"     <li>",
"      The heart",
"     </li>",
"     <li>",
"      The left pulmonary artery and the pulmonary veins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Structures seen in mid-esophagus include (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Mid-esophagus'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The aorta, which then evolves into the aortic arch",
"     </li>",
"     <li>",
"      The spine",
"     </li>",
"     <li>",
"      The azygous vein",
"     </li>",
"     <li>",
"      The thoracic duct",
"     </li>",
"     <li>",
"      The superior vena cava",
"     </li>",
"     <li>",
"      Left and right bronchi which evolve into the trachea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the echoendoscope is in the proximal esophagus, the following structures may be seen (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Proximal esophagus'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The subclavian artery",
"     </li>",
"     <li>",
"      The left common carotid artery and sometimes the brachiocephalic trunk",
"     </li>",
"     <li>",
"      The trachea",
"     </li>",
"     <li>",
"      The thyroid gland and sometimes the thymus gland",
"     </li>",
"     <li>",
"      The carotid arteries",
"     </li>",
"     <li>",
"      The jugular veins",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/1\">",
"      Snady H. Role of endoscopic ultrasonography in diagnosis, staging, and outcome of gastrointestinal diseases. Gastroenterologist 1994; 2:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/2\">",
"      Colin-Jones DG, R&ouml;sch T, Dittler HJ. Staging of gastric cancer by endoscopy. Endoscopy 1993; 25:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/3\">",
"      Yasuda K, Mukai H, Fujimoto S, et al. The diagnosis of pancreatic cancer by endoscopic ultrasonography. Gastrointest Endosc 1988; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/4\">",
"      Snady H, Bruckner H, Siegel J, et al. Endoscopic ultrasonographic criteria of vascular invasion by potentially resectable pancreatic tumors. Gastrointest Endosc 1994; 40:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/5\">",
"      Kimmey MB, Martin RW, Haggitt RC, et al. Histologic correlates of gastrointestinal ultrasound images. Gastroenterology 1989; 96:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/6\">",
"      Wiersema MJ, Wiersema LM. High-resolution 25-megahertz ultrasonography of the gastrointestinal wall: histologic correlates. Gastrointest Endosc 1993; 39:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/7\">",
"      Tio TL, Tytgat GN. Endoscopic ultrasonography of normal and pathologic upper gastrointestinal wall structure. Comparison of studies in vivo and in vitro with histology. Scand J Gastroenterol Suppl 1986; 123:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/8\">",
"      Bolondi L, Casanova P, Santi V, et al. The sonographic appearance of the normal gastric wall: an in vitro study. Ultrasound Med Biol 1986; 12:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/9\">",
"      Tio TL, Tytgat GN. Endoscopic ultrasonography in analysing peri-intestinal lymph node abnormality. Preliminary results of studies in vitro and in vivo. Scand J Gastroenterol Suppl 1986; 123:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/10\">",
"      Caletti GC, Bolondi L, Zani L, Lab&ograve; G. Technique of endoscopic ultrasonography investigation: esophagus, stomach and duodenum. Scand J Gastroenterol Suppl 1986; 123:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/11\">",
"      Lux G, Heyder N. Endoscopic ultrasonography of the pancreas. Technical aspects. Scand J Gastroenterol Suppl 1986; 123:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/12\">",
"      Kremkau FW, Taylor KJ. Artifacts in ultrasound imaging. J Ultrasound Med 1986; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     Snady H. Artifacts and techniques of endoscopic ultrasonography in investigating gastrointestinal pathologies and therapeutic options. In: Methods in Disease: Investigating the Gastrointestinal Tract, Preedy V, Watson R (Eds), Greenwich Med Media, London 1998. p.141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/14\">",
"      Grech P. Mirror-image artifact with endoscopic ultrasonography and reappraisal of the fluid-air interface. Gastrointest Endosc 1993; 39:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/15\">",
"      Bolondi L, Caletti G, Casanova P, et al. Problems and variations in the interpretation of the ultrasound feature of the normal upper and lower GI tract wall. Scand J Gastroenterol Suppl 1986; 123:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24597/abstract/16\">",
"      Eloubeidi MA, Tamhane A, Lopes TL, et al. Cervical esophageal perforations at the time of endoscopic ultrasound: a prospective evaluation of frequency, outcomes, and patient management. Am J Gastroenterol 2009; 104:53.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2657 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24597=[""].join("\n");
var outline_f24_1_24597=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17495194\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17495045\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Distal esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mid-esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Proximal esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17495194\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2657\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2657|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/9/38035\" title=\"diagnostic image 1\">",
"      EUS five layer pattern",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28310?source=related_link\">",
"      Complications of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1242?source=related_link\">",
"      Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=related_link\">",
"      Endoscopic ultrasound in esophageal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35509?source=related_link\">",
"      High frequency catheter endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4281?source=related_link\">",
"      Therapeutic endoscopic ultrasound",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_1_24598="Arsenic trioxide: Pediatric drug information";
var content_f24_1_24598=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Arsenic trioxide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"    see \"Arsenic trioxide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/32/25092?source=see_link\">",
"    see \"Arsenic trioxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trisenox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F999071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F999096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"      see \"Arsenic trioxide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute promyelocytic leukemia (APL), relapsed or refractory:",
"     </b>",
"     Children &ge;4 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction: 0.15 mg/kg/day; administer daily until bone marrow remission; maximum induction: 60 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Consolidation: 0.15 mg/kg/day starting 3-6 weeks after completion of induction therapy; maximum consolidation: 25 doses over a period of up to 5 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      APL initial treatment:",
"     </b>",
"     Limited data available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction, consolidation, and maintenance (Mathews, 2006): Dosing based on experience available for children &ge;3 years; however, age was not an exclusion criteria in clinical trial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Induction: 0.15 mg/kg/day (maximum dose: 10 mg); administer daily until bone marrow remission; maximum induction: 60 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Consolidation: 0.15 mg/kg/day (maximum dose: 10 mg) for 4 weeks, starting 4 weeks after completion of induction therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance: 0.15 mg/kg/dose (maximum dose: 10 mg) administered 10 days per month for 6 months, starting 4 weeks after completion of consolidation therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     In combination with tretinoin (Ravandi, 2009): Dosing based on experience available for adolescents &ge;14 years; however, age was not an exclusion criteria in clinical trial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Induction (beginning 10 days after initiation of tretinoin): 0.15 mg/kg/day until bone marrow remission; maximum induction: 75 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Consolidation: 0.15 mg/kg/day Monday through Friday for 4 weeks every 8 weeks for 4 cycles (weeks 1 to 4, 9 to 12, 17 to 20, and 25 to 28)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     APL, relapsed or refractory:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction: 0.15 mg/kg/day; administer daily until bone marrow remission; maximum induction: 60 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Consolidation: 0.15 mg/kg/day starting 3-6 weeks after completion of induction therapy; maximum consolidation: 25 doses over a period of up to 5 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Use with caution (systemic exposure to metabolites may be higher); may require dosage reduction; monitor closely for toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dialysis patients: Has not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Use with caution; severe hepatic impairment (Child-Pugh class C): Monitor closely for toxicity",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trisenox&reg;: 1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F999102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Dilute in 100-250 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS. Does not contain a preservative; properly discard unused portion. Do not mix with other medications. Infuse over 1-2 hours. If acute vasomotor reactions occur, may infuse over a maximum of 4 hours. Does not require administration via a central venous catheter; pH: 7.5-8.5",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F999089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Following dilution in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; stable for 24 hours at room temperature or 48 hours when refrigerated.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F999072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remission induction and consolidation in patients with relapsed or refractory acute promyelocytic leukemia (APL) characterized by t(15;17) translocation or PML/RAR-alpha gene expression (FDA approved in ages &ge;4 years and adults); has also been used in the initial treatment of APL and the treatment of myelodysplastic syndrome (MDS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F136755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Abnormal ECG (not QT prolongation), atrial dysrhythmia, chest pain, edema, facial edema, flushing, hyper-/hypotension, pallor, palpitation, QT interval &gt;500 msec,  tachycardia, torsade de pointes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, coma, confusion, depression, dizziness, fatigue, fever, headache, insomnia, pain, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, dermatitis, dry skin, erythema, hyperpigmentation, local exfoliation, petechia, pruritus, skin lesions, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, hyperglycemia, hyperkalemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, intermenstrual bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, abdominal tenderness, anorexia, appetite decreased, caecitis, constipation, diarrhea, dyspepsia, fecal incontinence, gastrointestinal hemorrhage, hemorrhagic diarrhea, loose stools, nausea, oral blistering, oral candidiasis, sore throat, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Incontinence, vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, APL differentiation syndrome, DIC, febrile neutropenia, hemorrhage, leukocytosis, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Edema, erythema, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain,  bone pain, limb pain, myalgia, neck pain, neuropathy, paresthesia, rigors, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, dry eye, eye irritation, eyelid edema, painful red eye",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Earache, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal failure, renal impairment, oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Breath sounds decreased, cough, crepitations, dyspnea, epistaxis, hemoptysis, hypoxia, nasopharyngitis, pleural effusion, postnasal drip, pulmonary edema, rales, rhonchi, sinusitis, tachypnea, upper respiratory tract infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Bacterial infection, diaphoresis increased, herpes simplex, injection site edema, herpes zoster, hypersensitivity, lymphadenopathy, night sweats, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute respiratory distress syndrome, AV block, capillary leak syndrome, CHF, heart block, hypoalbuminemia, hyponatremia, hypophosphatemia, lipase increased, mitochondrial myopathy, pancytopenia, peripheral neuropathy, pneumonitis, pulmonary infiltrate, respiratory distress, stomatitis, ventricular extrasystoles, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F999076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to arsenic or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13168173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Use with caution in patients with hepatic impairment; in patients with severe hepatic impairment, monitor closely for toxicity. Use with caution in patients with severe renal impairment; systemic exposure to metabolites may be higher; has not been studied in dialysis patients. Monitor electrolytes, CBC with differential, and coagulation parameters at least twice a week during induction and weekly during consolidation; more frequently if clinically indicated. Should be administered under the supervision of a physician experienced in acute leukemia management",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F999077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May prolong the QT interval. May lead to torsade de pointes or complete AV block",
"     <b>",
"      [U.S. Boxed Warnings]",
"     </b>",
"     . Risk factors for torsade de pointes include extent of prolongation, HF, a history of torsade de pointes, pre-existing QT interval prolongation, patients taking medications known to prolong the QT interval or potassium-wasting diuretics, and conditions which cause hypokalemia or hypomagnesemia. If possible, discontinue all medications known to prolong the QT interval.  A baseline 12-lead ECG, serum electrolytes (potassium, calcium, magnesium), and creatinine should be obtained prior to treatment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Correct electrolyte abnormalities prior to treatment and monitor potassium and magnesium levels during therapy (maintain potassium &gt;4 mEq/dL and magnesium &gt;1.8 mg/dL). If baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec, correct prior to treatment. If QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec during treatment, reassess, correct contributing factors, and consider temporarily withholding treatment. If syncope or irregular heartbeat develops during therapy, hospitalize patient and do not reinitiate therapy until QT",
"     <sub>",
"      c",
"     </sub>",
"     &lt;460 msec, electrolytes abnormalities are corrected, and syncope or irregular heartbeat has resolved. Monitor ECG weekly; more frequently if clinically indicated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     May cause retinoic-acid-acute promyelocytic leukemia (RA-APL) syndrome or APL differentiation syndrome (dyspnea, fever, weight gain, pulmonary infiltrates, and pleural or pericardial effusions) in patients with APL",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may be fatal. High-dose steroids (dexamethasone 10 mg I.V. twice daily for &ge;3 days; begin at initial presentation and taper over 2 weeks) have been used for treatment; in general, most patients may continue arsenic trioxide during treatment of APL differentiation syndrome. May lead to the development of hyperleukocytosis (leukocytes &ge;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ); did not correlate with baseline WBC counts and generally were not as high during consolidation as observed during induction treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F999088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid homeopathic products (arsenic is present in some homeopathic medications).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased resorptions, neural-tube defects, and ophthalmic abnormalities have been observed in animal studies. Arsenic crosses the human placenta. In studies of women exposed to high levels of arsenic from drinking water, cord blood levels were similar to maternal serum levels. Dimethylarsinic acid (DMA) was the form of arsenic found in the fetus. An increased risk of low birth weight and still births were observed in women who ingested high levels of dietary arsenic. Women of childbearing potential should avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F999104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline then weekly 12-lead ECG; monitor electrolytes, CBC with differential, and coagulation at baseline then at least twice weekly during induction and at least weekly during consolidation; more frequent monitoring may be necessary in unstable patients",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F999091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces apoptosis in APL cells via morphological changes and DNA fragmentation; also damages or degrades the fusion protein PML-RAR alpha",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F999093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : As",
"     <sup>",
"      III",
"     </sup>",
"     : 562 L; widely distributed throughout body tissues; orally administered arsenic trioxide distributes into the CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Arsenic trioxide is immediately hydrolyzed to the active form, arsenious acid (As",
"     <sup>",
"      III",
"     </sup>",
"     ) which is methylated (hepatically) to the less active pentavalent metabolites, monomethylarsonic acid (MMA",
"     <sup>",
"      v",
"     </sup>",
"     ) and dimethylarsinic acid (DMA",
"     <sup>",
"      v",
"     </sup>",
"     ) by methyltransferases; As",
"     <sup>",
"      III",
"     </sup>",
"     is also oxidized to the minor metabolite, arsenic acid (As",
"     <sup>",
"      v",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: AS",
"     <sup>",
"      III",
"     </sup>",
"     : 10-14 hours; MMA",
"     <sup>",
"      v",
"     </sup>",
"     : ~32 hours; DMA",
"     <sup>",
"      v",
"     </sup>",
"     : ~72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentrations: As",
"     <sup>",
"      III",
"     </sup>",
"     : At the end of infusion; MMA",
"     <sup>",
"      v",
"     </sup>",
"     and DMA",
"     <sup>",
"      v",
"     </sup>",
"     ; ~10-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (MMA",
"     <sup>",
"      v",
"     </sup>",
"     ,  DMA",
"     <sup>",
"      v",
"     </sup>",
"     , and 15% of a dose as unchanged As",
"     <sup>",
"      III",
"     </sup>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F999108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/32/25092?source=see_link\">",
"      see \"Arsenic trioxide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This medication can only be administered by intravenous infusion. Report immediately any redness, swelling, pain, or burning at infusion site. May cause dizziness, fatigue, blurred vision, nausea, vomiting, diarrhea, or decreased appetite (small, frequent meals, frequent mouth care, sucking lozenges, or chewing gum may help). Report immediately unexplained fever; respiratory difficulty; chest pain or palpitations; confusion, lightheadedness, or fainting; unusual joint, back, or muscle pain; or tingling or loss of feeling.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Au WY, Tam S, Fong BM, et al, \"Determinants of Cerebrospinal Fluid Arsenic Concentration in Patients With Acute Promyelocytic Leukemia on Oral Arsenic Trioxide Therapy,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(9):3587-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/18703707/pubmed\" id=\"18703707\" target=\"_blank\">",
"        18703707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Concha G, Vogler G, Lezcano D, et al, \"Exposure to Inorganic Arsenic Metabolites During Early Human Development,\"",
"      <i>",
"       Toxicol Sci",
"      </i>",
"      , 1998, 44(2):185-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/9742656/pubmed\" id=\"9742656\" target=\"_blank\">",
"        9742656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc,\" Food and Nutrition Board, Institute of Medicine.  National Academy of Sciences, Washington, DC: National Academy Press, 2001, 162-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox E, Razzouk BI, Widemann BC, et al, \"Phase 1 Trial and Pharmacokinetic Study of Arsenic Trioxide in Children and Adolescents With Refractory or Relapsed Acute Leukemia, Including Acute Promyelocytic Leukemia or Lymphoma,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(2):566-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/17959855/pubmed\" id=\"17959855\" target=\"_blank\">",
"        17959855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gore SD, Gojo I, Sekeres MA, et al, \"Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      ,  2010, 28(6):1047-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/20085935/pubmed\" id=\"20085935\" target=\"_blank\">",
"        20085935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathews V, George B, Chendamarai E, et al, \"Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(24):3866-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/20644086/pubmed\" id=\"20644086\" target=\"_blank\">",
"        20644086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathews V, George B, Lakshmi KM, et al, \"Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Durable Remissions With Minimal Toxicity,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(7):2627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/16352810/pubmed\" id=\"16352810\" target=\"_blank\">",
"        16352810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), \"Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 3, 2010.\" Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell BL, Moser B, Stock W, et al, \"Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(19):3751-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/20705755/pubmed\" id=\"20705755\" target=\"_blank\">",
"        20705755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell BL, Moser B, Stock W, et al, \"Effect of Consolidation With Arsenic Trioxide (As2O3) on Event-Free Survival (EFS) and Overall Survival (OS) Among Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL): North American Intergroup Protocol C9710,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(18s):2 [abstract 2 from 2007 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ravandi F, Estey E, Jones D, et al, \"Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(4):504-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/19075265/pubmed\" id=\"19075265\" target=\"_blank\">",
"        19075265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Von Ehrenstein OS, Guha Mazumder DN, Hira-Smith M, et al, \"Pregnancy Outcomes, Infant Mortality, and Arsenic in Drinking Water in West Bengal, India,\"",
"      <i>",
"       Am J Epidemiol",
"      </i>",
"      , 2006,163(7):662-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/16651647/pubmed\" id=\"16651647\" target=\"_blank\">",
"        16651647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang CY, Chang CC, Tsai SS, et al, \"Arsenic in Drinking Water and Adverse Pregnancy Outcome in an Arseniasis-Endemic Area in Northeastern Taiwan,\"",
"      <i>",
"       Environ Res",
"      </i>",
"      , 2003, 91(1):29-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/1/24598/abstract-text/12550085/pubmed\" id=\"12550085\" target=\"_blank\">",
"        12550085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16769 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24598=[""].join("\n");
var outline_f24_1_24598=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708626\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136731\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999071\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999096\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136716\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136702\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999102\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999089\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999072\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401582\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136755\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999076\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168173\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999077\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298770\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136710\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999088\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136712\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136723\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999104\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999091\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999093\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999108\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16769|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=related_link\">",
"      Arsenic trioxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/32/25092?source=related_link\">",
"      Arsenic trioxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_1_24599="Laryngeal anatomy";
var content_f24_1_24599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laryngeal anatomy in the coronal plane from a posterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Garrett, CG, Ossoff, RH. Hoarseness. Med Clin N Am 1999; 83:115. Copyright 1999 W.B. Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24599=[""].join("\n");
var outline_f24_1_24599=null;
var title_f24_1_24600="CLL marrow low";
var content_f24_1_24600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow aspirate in a patient with chronic lymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a bone marrow aspirate in a patient with chronic lymphocytic leukemia shows a monotonous infiltration with small round cells having only a thin rim of cytoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD and Anna J Mitus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24600=[""].join("\n");
var outline_f24_1_24600=null;
var title_f24_1_24601="Approach to the patient with an adnexal mass";
var content_f24_1_24601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with an adnexal mass",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/1/24601/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24601/contributors\">",
"     Michael G Muto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/1/24601/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24601/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24601/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/1/24601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24601/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/1/24601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adnexal mass (mass of the ovary, fallopian tube, or surrounding connective tissues) is a common gynecologic problem. In the United States, it is estimated that there is a 5 to 10 percent lifetime risk for women undergoing surgery for a suspected ovarian neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/1\">",
"     1",
"    </a>",
"    ]. Adnexal masses may be found in females of all ages, fetuses to the elderly, and there is a wide variety of types of masses (",
"    <a class=\"graphic graphic_table graphicRef69013 \" href=\"UTD.htm?20/40/21131\">",
"     table 1",
"    </a>",
"    ). The principal goals of the evaluation are to address acute conditions (eg, ectopic pregnancy) and to determine whether a mass is malignant.",
"   </p>",
"   <p>",
"    The initial approach to and an overview of the evaluation of patients with an adnexal mass are reviewed here. Management of an adnexal mass and other related topics are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"       \"Differential diagnosis of the adnexal mass\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"       \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33033?source=see_link\">",
"       \"Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link\">",
"       \"Management of an adnexal mass\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=see_link\">",
"       \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3883656\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the evaluation of a patient with an adnexal mass is to determine the most likely etiology of the mass. This process is often challenging, since there are many types of adnexal masses and a definitive diagnosis often requires surgical evaluation.",
"   </p>",
"   <p>",
"    The evaluation is guided in large part by the anatomic location of the mass and age and reproductive status of the patient. As an example, a solid ovarian mass in a postmenopausal woman raises a high suspicion of ovarian cancer. Alternatively, a fallopian tube mass accompanied by pain and bleeding in a woman of reproductive-age requires immediate pregnancy testing and exclusion of an ectopic pregnancy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11757752\">",
"    <span class=\"h2\">",
"     Excluding urgent conditions or malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adnexal mass may represent a serious health issue, a condition that requires urgent intervention (eg, ectopic pregnancy, adnexal torsion) or an ovarian or fallopian tube cancer (or malignant disease metastatic for a peritoneal cancer or other primary). A general evaluation is performed initially to confirm the presence of a mass and to identify patients who should be further evaluated for an urgent condition or for malignancy. For other patients, the general evaluation continues as the diagnostic evaluation. (See",
"    <a class=\"local\" href=\"#H25408488\">",
"     'General evaluation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3884018\">",
"     'Evaluation for urgent conditions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3884375\">",
"     'Evaluation for malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical features of patients with urgent conditions are fairly specific (eg, severe pain, first trimester bleeding, fever), and these represent a minority of patients.",
"   </p>",
"   <p>",
"    Similarly, few patients who present with an adnexal mass will ultimately be diagnosed with a malignancy. However, many patients will need to undergo an evaluation to full exclude malignancy, which may require follow-up with pelvic ultrasound for a prolonged period of time or surgical exploration. This is because malignancy must be excluded for any mass that is not clearly benign, including most complex masses (characterized on ultrasound by solid components, thick walls, septations, or other hyperechoic findings).",
"   </p>",
"   <p>",
"    The remaining patients include those with a simple ovarian cyst (characterized on ultrasound by an anechoic fluid filling the cyst cavity with thin walls), ovarian masses for which the ultrasound diagnosis is fairly certain (teratoma, endometrioma, hemorrhagic cyst), or other adnexal masses that are invariably benign (eg, paratubal or paraovarian cyst, broad ligament leiomyoma) (",
"    <a class=\"graphic graphic_table graphicRef69013 \" href=\"UTD.htm?20/40/21131\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2727391\">",
"    <span class=\"h2\">",
"     Anatomic location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic location helps to narrow the differential diagnosis. Most adnexal masses are ovarian, but some arise from a fallopian tube or the surrounding tissues or structures. The differential diagnosis of an adnexal mass is listed briefly here and is also shown in the table (",
"    <a class=\"graphic graphic_table graphicRef69013 \" href=\"UTD.htm?20/40/21131\">",
"     table 1",
"    </a>",
"    ) and discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H3883756\">",
"     'Imaging studies'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"     \"Differential diagnosis of the adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ovarian masses include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physiologic cysts (follicular or corpus luteum)",
"     </li>",
"     <li>",
"      Benign ovarian neoplasms (eg, endometrioma, mature teratoma [dermoid cyst])",
"     </li>",
"     <li>",
"      Ovarian cancer or metastatic disease from a non-ovarian primary cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A mass in the fallopian tube may be:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ectopic pregnancy",
"     </li>",
"     <li>",
"      Hydrosalpinx",
"     </li>",
"     <li>",
"      Fallopian tube cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ovary and fallopian tube are surrounded by the mesosalpinx or mesovarium, condensations of connective tissue that are part of the broad ligament (",
"    <a class=\"graphic graphic_figure graphicRef83001 \" href=\"UTD.htm?24/52/25412\">",
"     figure 1",
"    </a>",
"    ). Some adnexal masses arise from these tissues. In addition, some adnexal masses are adherent to the adnexa or derive from nearby structures: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paratubal or paraovarian cyst (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link&amp;anchor=H14#H14\">",
"       \"Differential diagnosis of the adnexal mass\", section on 'Paraovarian/paratubal cysts and other tubal and broad ligament neoplasms'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tuboovarian abscess (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Broad ligament leiomyoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Terminology and location'",
"      </a>",
"      ) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2727399\">",
"    <span class=\"h2\">",
"     Age and reproductive status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different types of adnexal masses are more likely depending upon the age and reproductive status of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2727408\">",
"    <span class=\"h3\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adnexal masses occur less frequently in children and adolescents than in reproductive-age women. However, when an adnexal mass is found in this patient population, there is a significant likelihood of adnexal torsion or an ovarian malignancy (approximately 10 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Germ cell tumors are the most common type of ovarian cancer in children and adolescents, comprising 35 percent compared with 20 percent in adults. The approach to adnexal masses in this age group is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=see_link\">",
"     \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2727416\">",
"    <span class=\"h3\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The great majority of adnexal masses occur in reproductive-age patients (including postmenarchal adolescents), and most of these masses are benign [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/7\">",
"     7",
"    </a>",
"    ]. This is because the pathogenesis of many benign adnexal masses is associated with reproductive function. Pregnancy-related etiologies (eg, ectopic pregnancy, corpus luteum cyst) occur exclusively in reproductive-age patients by definition. Many other types of adnexal masses are associated with the menstrual cycle or reproductive hormones (eg, follicular cysts, endometriomas) and are common findings found in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link&amp;anchor=H6#H6\">",
"     \"Differential diagnosis of the adnexal mass\", section on 'Premenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ovarian or fallopian tube cancer is less likely in premenopausal than postmenopausal women, but the possibility of malignancy should be considered in all patients. The incidence of ovarian cancer increases with age (eg, 1.8 to 2.2 per 100,000 women age 20 to 29 versus 9.0 to 15.2 per 100,000 women age 40 to 49 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/8\">",
"     8",
"    </a>",
"    ]). (See",
"    <a class=\"local\" href=\"#H3884375\">",
"     'Evaluation for malignancy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092134#H6092134\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2727424\">",
"    <span class=\"h3\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excluding malignancy is the main priority in postmenopausal women with an adnexal mass (the average age of diagnosis of ovarian cancer in the United States is 63 years old) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/8\">",
"     8",
"    </a>",
"    ]. Many of these women will require a surgical evaluation. (See",
"    <a class=\"local\" href=\"#H3884375\">",
"     'Evaluation for malignancy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092134#H6092134\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urgent conditions (eg, adnexal torsion, tuboovarian abscess) may also occur in postmenopausal women, but are less common and are more likely to be associated with malignancy. (See",
"    <a class=\"local\" href=\"#H3884018\">",
"     'Evaluation for urgent conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25408488\">",
"    <span class=\"h1\">",
"     GENERAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with an adnexal mass typically present with gynecologic symptoms and a mass is identified on pelvic imaging. Alternatively, an adnexal mass is discovered incidentally on pelvic examination or imaging in many patients.",
"   </p>",
"   <p>",
"    Patients with a known or suspected adnexal mass should undergo a general evaluation to confirm the presence of a mass and determine its characteristics and any associated symptoms or physical findings. Patients should be assessed for features that indicate immediate intervention or suggest malignancy, and these patients should undergo a focused evaluation for these conditions. (See",
"    <a class=\"local\" href=\"#H3884018\">",
"     'Evaluation for urgent conditions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3884375\">",
"     'Evaluation for malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25412815\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic pain or pressure is the most common symptom associated with an adnexal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/9\">",
"     9",
"    </a>",
"    ]. Some women present with genital tract bleeding. Ovarian cancer may be associated with pelvic or abdominal symptoms or, for particular histologic types (eg, sex cord-stromal tumors), with symptoms related to hormone production by the tumor.",
"   </p>",
"   <p>",
"    Patients who present with symptoms or findings suggestive of an adnexal mass should undergo pelvic examination and imaging to confirm whether a mass is present (see",
"    <a class=\"local\" href=\"#H25412823\">",
"     'Physical examination'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3883756\">",
"     'Imaging studies'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    For patient with a known adnexal mass, the clinician should inquire about associated symptoms. Symptom patterns that suggest a particular etiology help to guide further evaluation or management.",
"   </p>",
"   <p>",
"    If pain or pressure is present, the characteristics of the discomfort should be elicited, including the acuity of onset, location, duration, whether it is constant or intermittent, and whether it is associated with any other factors (eg, menstrual cycle). An adnexal mass that is associated with severe pain, particularly of abrupt onset, or pelvic pain in a pregnant woman requires immediate evaluation. The relationship of pain symptoms to particular types of adnexal masses is discussed below. (See",
"    <a class=\"local\" href=\"#H3884018\">",
"     'Evaluation for urgent conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Benign masses that do not require immediate intervention may also present with pelvic pain. Ovarian physiologic cysts or neoplasms are typically associated with a dull, achy pain that is usually localized to the side of the mass or may be asymptomatic, as noted above. An endometrioma may be associated with dysmenorrhea or dyspareunia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link&amp;anchor=H7#H7\">",
"     \"Differential diagnosis of the adnexal mass\", section on 'Physiologic/functional cysts'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link&amp;anchor=H11#H11\">",
"     \"Differential diagnosis of the adnexal mass\", section on 'Benign ovarian neoplasms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient who presents with an adnexal mass and vaginal bleeding and who may be pregnant should have pregnancy testing. Types of adnexal masses that are particular to pregnancy are an ectopic pregnancy, which requires urgent intervention, or a corpus luteum cyst. (See",
"    <a class=\"local\" href=\"#H5378314\">",
"     'Laboratory evaluation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8778632\">",
"     'First trimester bleeding or pain'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients should be asked about a history of fever or vaginal discharge. Patients who complain of fever and vaginal discharge and are found to have an adnexal mass should be evaluated for a tuboovarian abscess. The combination of a tubal mass and a history of pelvic inflammatory disease may also represent a hydrosalpinx. Persistent serosanguineous vaginal discharge without fever has been associated with fallopian tube cancer. (See",
"    <a class=\"local\" href=\"#H8778667\">",
"     'Fever'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link&amp;anchor=H6099199#H6099199\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Pelvic and abdominal symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women should also be asked about a history of infertility, since an endometrioma or hydrosalpinx may contribute to infertility. In addition, infertility is associated with an increased risk of ovarian tumors of low malignant potential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"     \"Pathogenesis and treatment of infertility in women with endometriosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link&amp;anchor=H11#H11\">",
"     \"Reproductive surgery for female infertility\", section on 'Salpingectomy before in vitro fertilization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092174#H6092174\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Infertility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The medical history should include questions about risk factors and symptoms associated with ovarian or fallopian tube cancer (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"     table 2",
"    </a>",
"    ). In addition to other risk factors, age and reproductive status are important factors. (See",
"    <a class=\"local\" href=\"#H2727399\">",
"     'Age and reproductive status'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3884375\">",
"     'Evaluation for malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25412823\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough pelvic examination is performed to assess for an adnexal mass in a symptomatic patient and determine its characteristics. The approaches to the pelvic examination in adults and in children are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=see_link&amp;anchor=H13#H13\">",
"     \"The gynecologic history and pelvic examination\", section on 'Pelvic examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=see_link\">",
"     \"Gynecologic examination of the newborn and child\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A finding of an adnexal mass on pelvic examination should be further evaluated with pelvic imaging. Imaging may reveal an adnexal mass, no mass, or a mass that derives from another anatomic location in the genital (eg, uterine leiomyoma), gastrointestinal (eg, mucocele of the appendix), or urinary (eg, urachal cyst) tracts or other sites (eg, enlarged mesenteric lymph nodes). (See",
"    <a class=\"local\" href=\"#H3883756\">",
"     'Imaging studies'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The absence of an adnexal mass on examination does not fully exclude the presence of a pelvic mass. Small adnexal masses are difficult to palpate due to the deep anatomic location of the ovary. In addition, larger masses can float out of the pelvis and be difficult to feel. Ovaries are not usually palpable in postmenopausal women, and a finding of a palpable ovary in this population should prompt pelvic imaging to assess for an ovarian or tubal neoplasm. &nbsp;",
"   </p>",
"   <p>",
"    The size, consistency, and mobility of a mass, if present, should be noted. Features that are suggestive of malignancy include a solid mass that is irregular or fixed or is associated with posterior cul-de-sac nodularity. On the other hand, endometriomas and tuboovarian abscesses are benign lesions that may be fixed and irregular. Posterior cul-de-sac nodularity is highly suspicious for malignancy in a postmenopausal woman, but may signify endometriosis in a premenopausal woman.",
"   </p>",
"   <p>",
"    Patients with an inflammatory process exhibit tenderness with palpation of the adnexal mass (eg, tuboovarian abscess). However, some patients with an ovarian neoplasm have tenderness on pelvic examination.",
"   </p>",
"   <p>",
"    Rectovaginal examination is performed to allow palpation of the ovary posteriorly. A rectal mass or positive fecal occult blood testing is not usually associated with an adnexal mass. These findings should be noted, if present, and further evaluated for colorectal cancer or other conditions, as appropriate. A rectal mass is an uncommon finding in epithelial ovarian cancer (EOC) since direct transmural extension is rare. Infrequently, rectal bleeding may occur in cases of rectal endometriosis or clear cell or endometrioid cancers arising in endometriotic implants in the rectal wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7272?source=see_link\">",
"     \"Etiology of lower gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24858?source=see_link\">",
"     \"Rectovaginal or bowel endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abdominal examination includes assessment for abdominal distention and ascites",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an abdominal mass. The diagnosis of malignancy is almost certain in patients with both a fixed, irregular pelvic mass and an abdominal mass or ascites.",
"   </p>",
"   <p>",
"    If malignancy is suspected, the examination should also include sites of cancer that may metastasize to the ovaries (eg, stomach, breast). If there is a moderate to high suspicion of ovarian cancer, further examination should be performed of potential sites of EOC metastases (rectum, liver, spleen, lungs, inguinal or supraclavicular lymph nodes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link&amp;anchor=H9#H9\">",
"     \"Epithelial ovarian cancer: Pathology\", section on 'Patterns of spread'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link&amp;anchor=H13733571#H13733571\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Assessing for metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3883756\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of adnexal masses with ultrasound and other imaging modalities is discussed in detail separately. A brief summary is included here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic ultrasound is the imaging study of choice for the evaluation of an adnexal mass. Ultrasound is relatively less expensive than other imaging modalities and its diagnostic performance is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both a transvaginal and transabdominal ultrasound should be obtained in most patients. Transabdominal ultrasound is better tolerated and is more helpful in visualizing abdominal processes. Transvaginal ultrasound provides better resolution of pelvic structures with less artifact and does not require a distended bladder.",
"   </p>",
"   <p>",
"    A definitive diagnosis of the type of adnexal mass can be made only with histologic evaluation, not with imaging. However, simple ovarian cysts, hemorrhagic cysts, endometriomas, and teratomas often have characteristic ultrasound features that are highly predictive of the histologic diagnosis.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging should be used as a second imaging study if further imaging is needed to decide whether to proceed with surgical evaluation. Ovarian masses with an indeterminate appearance on ultrasound are typically hemorrhagic masses in which mural clot can appear solid on ultrasound, mature teratomas with an atypical appearance, or solid ovarian neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5378314\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation depends upon the clinical scenario:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy testing with a urine or serum human beta chorionic gonadotropin should be performed in any reproductive-age woman who presents with an adnexal mass.",
"     </li>",
"     <li>",
"      A complete blood count should be drawn if anemia is suspected due to bleeding in the setting of an ectopic pregnancy, ruptured or hemorrhagic ovarian cyst, or to assess for leukocytosis in patients with a tuboovarian abscess.",
"     </li>",
"     <li>",
"      Laboratory testing to evaluate for malignancy is discussed below. (See",
"      <a class=\"local\" href=\"#H543206\">",
"       'Laboratory studies'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3884018\">",
"    <span class=\"h1\">",
"     EVALUATION FOR URGENT CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who present with an abrupt onset of severe pain, first trimester bleeding, or fever require evaluation in an emergency department or other urgent care setting. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8778632\">",
"    <span class=\"h2\">",
"     First trimester bleeding or pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adnexal masses found in early pregnancy include ectopic pregnancy or corpus luteum cyst. A corpus luteum is a normal finding, and is not associated with vaginal bleeding or pain. These two masses are usually easily differentiated on pelvic ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link&amp;anchor=H9#H9\">",
"     \"Differential diagnosis of the adnexal mass\", section on 'Pregnancy-related etiologies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3884026\">",
"    <span class=\"h3\">",
"     Ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of an adnexal mass (which is not consistent with a corpus luteum) in a pregnant patient with no confirmed intrauterine pregnancy, particularly if accompanied by pelvic pain or vaginal bleeding should be considered an ectopic pregnancy until proven otherwise. Immediate evaluation and treatment are required for this potentially life-threatening condition. The fallopian tube is the most common site of an ectopic pregnancy, although ovarian pregnancy may also occur.",
"   </p>",
"   <p>",
"    The diagnosis and management of ectopic pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=see_link\">",
"     \"Ultrasonography of pregnancy of unknown location\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8778641\">",
"    <span class=\"h2\">",
"     Acute pelvic or abominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abrupt onset of severe pain in a woman with an adnexal mass may be associated with adnexal torsion, rupture of an ovarian cyst, or a ruptured ectopic pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3884034\">",
"    <span class=\"h3\">",
"     Adnexal torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adnexal torsion typically presents with an abrupt onset of severe pelvic pain, and is often accompanied by nausea and vomiting. Urgent surgical treatment is required to avoid ischemic injury and loss of ovarian and tubal function. &nbsp;",
"   </p>",
"   <p>",
"    The diagnosis and management of adnexal torsion are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link\">",
"     \"Ovarian and fallopian tube torsion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3884042\">",
"    <span class=\"h3\">",
"     Ruptured or hemorrhagic ovarian cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic presentation of a ruptured ovarian cyst is an abrupt onset of severe pain in the mid-menstrual cycle immediately following sexual intercourse. In ovulatory patients, a follicular cyst forms mid-cycle, followed by a corpus luteum. These physiologic cysts may rupture due to pressure on the ovary during sexual intercourse. Patients with a ruptured cyst may also present at other times of the menstrual cycle or without a recent history of intercourse. A cyst may also become hemorrhagic without rupture. Immediate surgical intervention is required only if there is concern that brisk bleeding from the cyst may cause anemia or hemodynamic instability. Other patients may be managed with pain management and follow-up for resolution of the pain and the mass.",
"   </p>",
"   <p>",
"    The diagnosis and management of a ruptured ovarian cyst are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link\">",
"     \"Evaluation and management of ruptured ovarian cyst\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8778667\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an adnexal mass and fever should be evaluated for a tuboovarian abscess. Alternatively, this presentation may represent a periappendiceal abscess or diverticular abscess. Infrequently, fever is associated with adnexal torsion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3884050\">",
"    <span class=\"h3\">",
"     Tuboovarian abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic presentation of a tuboovarian abscess includes acute lower abdominal pain, fever, chills, vaginal discharge, and an adnexal mass. Pelvic imaging typically shows a complex multilocular mass that obliterates normal adnexal architecture. Timely diagnosis and management are required to diagnose or avoid sepsis and to prevent further damage to the ovaries and fallopian tubes.",
"   </p>",
"   <p>",
"    The diagnosis and management of a tuboovarian abscess are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43560?source=see_link\">",
"     \"Management and complications of tuboovarian abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3884375\">",
"    <span class=\"h1\">",
"     EVALUATION FOR MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the principal goals of the evaluation of an adnexal mass is to determine whether it is benign or malignant.",
"   </p>",
"   <p>",
"    The types of malignant adnexal masses include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"     \"Differential diagnosis of the adnexal mass\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian cancer &ndash; The most common histologic type is epithelial ovarian carcinoma (EOC). Other types of ovarian cancer include germ cell tumors and sex cord-stromal tumors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link&amp;anchor=H4#H4\">",
"       \"Epithelial ovarian cancer: Pathology\", section on 'Histopathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fallopian tube or peritoneal carcinoma &ndash; Women with peritoneal carcinoma may present with or without an adnexal mass. High grade serous EOC, fallopian tube, and peritoneal carcinomas are considered a single clinical entity to their shared clinical behavior and treatment and there is accumulating evidence of a common pathogenesis. We will use the term EOC to refer to this group of malignancies in the discussion that follows. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=see_link\">",
"       \"Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metastatic disease from another primary cancer &ndash; Gastric and breast cancer are the most common malignancies that metastasize to the ovaries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link&amp;anchor=H12#H12\">",
"       \"Differential diagnosis of the adnexal mass\", section on 'Malignant ovarian neoplasms'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Excluding malignancy is typically a two-phase process. An initial evaluation is performed to establish the degree of clinical suspicion that a mass is malignant. If malignancy is suspected, surgical exploration is performed to make a definitive diagnosis.",
"   </p>",
"   <p>",
"    The likelihood that an adnexal mass is malignant depends mainly upon one or more of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging study findings that are consistent with malignancy",
"     </li>",
"     <li>",
"      Age or menopausal status",
"     </li>",
"     <li>",
"      Risk factors",
"     </li>",
"     <li>",
"      Laboratory results",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If malignancy is suspected based upon these factors, surgical exploration is required to obtain a specimen for histologic diagnosis. Unfortunately, there is no minimally invasive biopsy technique for ovarian cancer. This is because patients with early stage disease (ie, no malignant cells in ascites or peritoneal cytology) benefit from removal of the adnexal mass intact, since opening the mass results in a more advanced stage and adversely affects prognosis (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60565 \" href=\"UTD.htm?14/11/14526\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Thus, image-guided ovarian biopsy is not performed and, unfortunately, many women undergo surgical procedures to identify the few who have a malignancy. As an example, in a large ovarian cancer screening randomized trial, among 570 women who underwent surgical evaluation for suspected ovarian cancer, 20 cases of malignancy were found (3.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link&amp;anchor=H25#H25\">",
"     \"Oophorectomy and ovarian cystectomy\", section on 'Spillage of malignant cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decisions regarding surgical evaluation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link\">",
"     \"Management of an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for ovarian cancer in women who are asymptomatic and have no adnexal mass is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"     \"Screening for ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8777709\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the initial evaluation is to determine the degree of clinical suspicion of malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8777717\">",
"    <span class=\"h3\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age and menopausal status of the patient help to guide the process of evaluation, with the highest proportion of malignancy found in an adnexal mass in a postmenopausal woman or a child or adolescent, as discussed above. (See",
"    <a class=\"local\" href=\"#H2727399\">",
"     'Age and reproductive status'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with an adnexal mass should be asked about symptoms associated with ovarian cancer. Patients with ovarian cancer may present with symptoms of pelvic or abdominal pain or pressure, bloating, or gastrointestinal or urinary tract symptoms (",
"    <a class=\"graphic graphic_table graphicRef76135 \" href=\"UTD.htm?28/28/29132\">",
"     table 5",
"    </a>",
"    ). These symptoms are typically mild to moderate and develop over a period of weeks or months.",
"   </p>",
"   <p>",
"    Alternatively, it is common for ovarian cancer to be asymptomatic or to present at an advanced stage with an acute condition and associated symptoms (eg, bowel obstruction, pleural effusion). Infrequently, a malignant mass may rupture or torse and present with acute pain.",
"   </p>",
"   <p>",
"    Ovarian tumors that secrete hormones may present with symptoms related to estrogen excess (abnormal uterine bleeding) or androgen excess (virilization or hirsutism) (",
"    <a class=\"graphic graphic_table graphicRef76135 \" href=\"UTD.htm?28/28/29132\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Symptoms of ovarian cancer are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"     \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link&amp;anchor=H27#H27\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link&amp;anchor=H5#H5\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Clinical manifestations overview'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=see_link&amp;anchor=H4401840#H4401840\">",
"     \"Overview of sex cord-stromal tumors of the ovary\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of risk factors for EOC or other histologic types of ovarian cancer is a key determinant of clinical suspicion of the disease (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"     table 2",
"    </a>",
"    ). Patients with an adnexal mass should be asked about a family history of ovarian, breast, uterine, or colon cancer. Those with a family history suggestive of a hereditary ovarian cancer syndrome (",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutation or Lynch syndrome) should be counseled about genetic testing. Women with a hereditary ovarian cancer syndrome are at a greatly increased risk of ovarian cancer (",
"    <a class=\"graphic graphic_table graphicRef68548 \" href=\"UTD.htm?7/40/7821\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57830 \" href=\"UTD.htm?2/0/2049\">",
"     figure 2",
"    </a>",
"    ) and should undergo surgical evaluation if any suspicious adnexal mass is found. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092142#H6092142\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H517940\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination findings that are associated with malignancy are discussed above. (See",
"    <a class=\"local\" href=\"#H25412823\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539629\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic ultrasound is the first line imaging study for the evaluation of an adnexal mass.",
"   </p>",
"   <p>",
"    The sensitivity of pelvic ultrasound for the diagnosis of ovarian cancer ranged from 86 to 91 percent and the specificity ranged from 68 to 83 percent in a large meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/10\">",
"     10",
"    </a>",
"    ]. Use of a second imaging study after ultrasound is reasonable if a clinician cannot determine whether surgical evaluation is warranted based upon the results of ultrasound and the other components of the initial evaluation. The diagnostic performance of ultrasound compared with other imaging modalities is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link&amp;anchor=H445316#H445316\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\", section on 'Ultrasound versus other diagnostic methods'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sonographic features suggestive of a malignant adnexal mass are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79259 \" href=\"UTD.htm?1/0/1035\">",
"     table 7",
"    </a>",
"    ) and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional imaging studies may be necessary to evaluate the abdomen or other sites in patients with suspected metastatic ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link&amp;anchor=H13733571#H13733571\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Assessing for metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543206\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum biomarkers contribute to the evaluation of an adnexal mass for malignancy; however, their utility is limited.",
"   </p>",
"   <p>",
"    Preoperative measurement of biomarkers in women with possible ovarian cancer has several additional functions. A baseline level is established for use for further monitoring during and after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/7,15\">",
"     7,15",
"    </a>",
"    ]. In addition, biomarkers may play a role in predicting whether optimal cytoreduction is feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24601/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H9#H9\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Predicting optimal cytoreduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of serum biomarkers for ovarian cancer screening is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for ovarian cancer\", section on 'Tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5379592\">",
"    <span class=\"h4\">",
"     Serum markers for epithelial ovarian carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum CA 125 is the most commonly used laboratory test for the evaluation of adnexal masses for EOC. In our practice, we measure CA 125 in all postmenopausal women with an adnexal mass. In premenopausal women, we measure a serum CA 125",
"    <strong>",
"     only",
"    </strong>",
"    if the ultrasound appearance of a mass raises sufficient suspicion of malignancy to warrant a repeat ultrasound or surgical evaluation. Biomarkers that are used to decide whether to refer a patient with suspected EOC to a gynecologic oncologist are OVA1 and the Risk of Malignancy Algorithm.",
"   </p>",
"   <p>",
"    Choosing a serum biomarker and use of biomarkers in the management of a patient with an adnexal are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33033?source=see_link\">",
"     \"Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link&amp;anchor=H5079233#H5079233\">",
"     \"Management of an adnexal mass\", section on 'Suspected malignancy or uncertain etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5378980\">",
"    <span class=\"h4\">",
"     Serum markers for other histologic types",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germ cell and sex cord-stromal tumors may secrete hormones or other substances that can be detected preoperatively to contribute to the diagnostic evaluation. In many cases, however, the diagnosis of these histologic types is made only upon postoperative pathology evaluation of the ovary. Serum markers associated with these histologic types are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinical scenarios in which markers for these tumors should be drawn include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A child or adolescent who presents with an adnexal mass, since the most likely histology of an ovarian neoplasm is a germ cell tumor in this population.",
"     </li>",
"     <li>",
"      Patients with an adnexal mass who present with symptoms or signs of estrogen excess (abnormal uterine bleeding) or androgen excess (virilization or hirsutism) may have a germ cell or sex cord-stromal tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of these conditions is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=see_link&amp;anchor=H727968#H727968\">",
"     \"Overview of sex cord-stromal tumors of the ovary\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link&amp;anchor=H6#H6\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Diagnosis overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8777733\">",
"    <span class=\"h2\">",
"     Surgical exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical exploration is performed if the initial evaluation results in sufficient suspicion of a malignant adnexal mass. Surgical evaluation allows a definitive histologic diagnosis. If a malignancy is present, the surgeon may proceed with staging and cytoreduction. The steps of this procedure are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link&amp;anchor=H10104048#H10104048\">",
"     \"Management of an adnexal mass\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5379833\">",
"    <span class=\"h1\">",
"     REFERRAL TO A SPECIALIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a complex adnexal mass, findings suggestive of metastatic epithelial ovarian cancer (EOC), fallopian tube or peritoneal carcinoma, or laboratory testing suggestive of ovarian cancer (eg, elevated serum CA 125) should be referred to a gynecologist or gynecologic oncologist for further evaluation.",
"   </p>",
"   <p>",
"    Patients in whom there is a high suspicion of EOC should be referred to a gynecologic oncologist. There is evidence that prognosis is improved when EOC staging and cytoreduction is performed by a gynecologic oncologist. Criteria for referral to a gynecologic oncologist are shown in the table and are discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef55063 \" href=\"UTD.htm?7/38/7787\">",
"     table 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link&amp;anchor=H15998736#H15998736\">",
"     \"Management of an adnexal mass\", section on 'Referral to a specialist'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=see_link\">",
"       \"Patient information: Ovarian cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/27/39346?source=see_link\">",
"       \"Patient information: Ovarian cysts (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/20/2371?source=see_link\">",
"       \"Patient information: Ovarian cysts (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"       \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An adnexal mass (mass of the ovary, fallopian tube, or surrounding connective tissue) is a common gynecologic problem. An adnexal mass may be found in females of all ages, fetuses to the elderly, and there is a wide variety of etiologies (",
"      <a class=\"graphic graphic_table graphicRef69013 \" href=\"UTD.htm?20/40/21131\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with an adnexal mass present with symptoms or physical examination findings. Pelvic pain or pressure is the most common symptom of an adnexal mass. Other potential symptoms or signs include abnormal genital tract bleeding, abdominal distension, ascites, or hirsutism. Many adnexal masses are asymptomatic and the mass is discovered as an incidental finding on pelvic imaging. (See",
"      <a class=\"local\" href=\"#H25412815\">",
"       'Medical history'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The goal of the evaluation of a patient with an adnexal mass is to determine the most likely etiology of the mass. The process of evaluation includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A general evaluation to confirm the presence and anatomic location of the mass and to identify any associated symptoms or physical findings. (See",
"      <a class=\"local\" href=\"#H25408488\">",
"       'General evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A focused evaluation for conditions that require immediate treatment for patients who present with first trimester bleeding, acute pain, or fever. (See",
"      <a class=\"local\" href=\"#H3884018\">",
"       'Evaluation for urgent conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A focused evaluation to exclude malignancy if the results of the general evaluation raise the suspicion that the adnexal mass is malignant. (See",
"      <a class=\"local\" href=\"#H3884375\">",
"       'Evaluation for malignancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The medical history includes questions regarding symptoms associated with an adnexal mass and risk factors for ovarian or fallopian tube cancer (",
"      <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"       table 2",
"      </a>",
"      ). A thorough pelvic examination is performed to assess for an adnexal mass and determine its characteristics. Features that are suggestive of malignancy include a solid mass that is irregular or fixed or is associated with posterior cul-de-sac nodularity. On the other hand, some benign lesions may have these features. (See",
"      <a class=\"local\" href=\"#H25412815\">",
"       'Medical history'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25412823\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pelvic ultrasound is the first line imaging study for the evaluation of an adnexal mass. Ultrasound is relatively less expensive than other imaging modalities and its diagnostic performance is similar. Use of a second imaging study after ultrasound is reasonable if a clinician cannot determine whether surgical evaluation is warranted based upon the results of ultrasound and the other components of the initial evaluation. Sonographic features of a malignant adnexal mass are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef79259 \" href=\"UTD.htm?1/0/1035\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3883756\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation includes a pregnancy test in patients of reproductive-age and tests to evaluate for malignancy or other conditions. (See",
"      <a class=\"local\" href=\"#H5378314\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7972563\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to acknowledge Dr. Mitchel S Hoffman, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/1\">",
"      National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/2\">",
"      You W, Dainty LA, Rose GS, et al. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol 2005; 105:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/3\">",
"      Oltmann SC, Garcia N, Barber R, et al. Can we preoperatively risk stratify ovarian masses for malignancy? J Pediatr Surg 2010; 45:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/4\">",
"      Cass DL, Hawkins E, Brandt ML, et al. Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period. J Pediatr Surg 2001; 36:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/5\">",
"      Brown MF, Hebra A, McGeehin K, Ross AJ 3rd. Ovarian masses in children: a review of 91 cases of malignant and benign masses. J Pediatr Surg 1993; 28:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/6\">",
"      Hassan E, Creatsas G, Deligeorolgou E, Michalas S. Ovarian tumors during childhood and adolescence. A clinicopathological study. Eur J Gynaecol Oncol 1999; 20:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/7\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 2007; 110:201.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/ (Accessed on September 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/9\">",
"      Givens V, Mitchell GE, Harraway-Smith C, et al. Diagnosis and management of adnexal masses. Am Fam Physician 2009; 80:815.",
"     </a>",
"    </li>",
"    <li>",
"     Myers ER, Bastian LA, Havrilesky LJ, et al. Management of Adnexal Mass. Evidence Report/Technology Assessment No.130 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025). AHRQ Publication No. 06-E004, Agency for Healthcare Research and Quality, Rockville, MD February 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/11\">",
"      Spencer JA, Ghattamaneni S. MR imaging of the sonographically indeterminate adnexal mass. Radiology 2010; 256:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/12\">",
"      Webb MJ, Decker DG, Mussey E, Williams TJ. Factor influencing survival in Stage I ovarian cancer. Am J Obstet Gynecol 1973; 116:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/13\">",
"      Sainz de la Cuesta R, Goff BA, Fuller AF Jr, et al. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/14\">",
"      Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/15\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24601/abstract/16\">",
"      Kang S, Kim TJ, Nam BH, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol 2010; 101:13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3207 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-8FC26C7E2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24601=[""].join("\n");
var outline_f24_1_24601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3883656\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11757752\">",
"      Excluding urgent conditions or malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2727391\">",
"      Anatomic location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2727399\">",
"      Age and reproductive status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2727408\">",
"      - Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2727416\">",
"      - Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2727424\">",
"      - Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25408488\">",
"      GENERAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25412815\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25412823\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3883756\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5378314\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3884018\">",
"      EVALUATION FOR URGENT CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8778632\">",
"      First trimester bleeding or pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3884026\">",
"      - Ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8778641\">",
"      Acute pelvic or abominal pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3884034\">",
"      - Adnexal torsion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3884042\">",
"      - Ruptured or hemorrhagic ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8778667\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3884050\">",
"      - Tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3884375\">",
"      EVALUATION FOR MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8777709\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8777717\">",
"      - Medical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H517940\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H539629\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H543206\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5379592\">",
"      Serum markers for epithelial ovarian carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5378980\">",
"      Serum markers for other histologic types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8777733\">",
"      Surgical exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5379833\">",
"      REFERRAL TO A SPECIALIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7972563\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3207\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3207|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/52/25412\" title=\"figure 1\">",
"      Uterine broad ligament",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/0/2049\" title=\"figure 2\">",
"      Lynch syndrome cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3207|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/40/21131\" title=\"table 1\">",
"      Differential dx adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/59/12221\" title=\"table 2\">",
"      Risk factors ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 3\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/11/14526\" title=\"table 4\">",
"      Staging fallopian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/28/29132\" title=\"table 5\">",
"      Consensus statement ov ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/40/7821\" title=\"table 6\">",
"      Cancer risks BRCA1 and BRCA2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/0/1035\" title=\"table 7\">",
"      Sonographic findings ovarian CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/4/24653\" title=\"table 8\">",
"      Ovarian tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/38/7787\" title=\"table 9\">",
"      Referral to gyn oncologist",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=related_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=related_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7272?source=related_link\">",
"      Etiology of lower gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=related_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43560?source=related_link\">",
"      Management and complications of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=related_link\">",
"      Management of an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=related_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=related_link\">",
"      Ovarian cysts and neoplasms in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=related_link\">",
"      Overview of sex cord-stromal tumors of the ovary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=related_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=related_link\">",
"      Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=related_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/20/2371?source=related_link\">",
"      Patient information: Ovarian cysts (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/27/39346?source=related_link\">",
"      Patient information: Ovarian cysts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24858?source=related_link\">",
"      Rectovaginal or bowel endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33033?source=related_link\">",
"      Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=related_link\">",
"      The gynecologic history and pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=related_link\">",
"      Ultrasonography of pregnancy of unknown location",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_1_24602="Genetic counseling and testing";
var content_f24_1_24602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic counseling and testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/1/24602/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24602/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24602/contributors\">",
"     Wendy Kohlmann, MS, CGC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24602/contributors\">",
"     Vickie Venne, MS, CGC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/1/24602/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24602/contributors\">",
"     Anne Slavotinek, MBBS, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/1/24602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/1/24602/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/1/24602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inherited nature of disease has long been recognized. Genetics initially sought to explain the cause of rare diseases with a single gene Mendelian inheritance pattern, such as cystic fibrosis or Huntington disease. Recent discoveries have led to an exponentially increased understanding of the causes of many common diseases, in which disease risk often is determined by the combined effects of genetic and environmental factors.",
"   </p>",
"   <p>",
"    Gene alterations that confer increased risk for adult onset conditions such as cancer, diabetes, cardiovascular, and other common diseases have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/1\">",
"     1",
"    </a>",
"    ]. The hope is that identification of heightened genetic risk will allow specifically tailored interventions, encourage lifestyle changes, and ultimately prevent disease. As an example, in the case of women identified with BRCA gene mutations, a prospective multicenter study found that women who underwent risk-reducing salpingo-oophorectomy, compared to those who did not, had lower all-cause mortality (HR 0.40, 95% CI 0.26-76) and a lower risk of cancer incidence and cancer-specific mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/2\">",
"     2",
"    </a>",
"    ]. There were no breast cancers in those BRCA women who underwent risk-reducing mastectomy, compared to breast cancer occurrence in 98 of 1372 women who did not have a mastectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    Targeting appropriate patients for counseling and testing is key to the successful transfer of genetic research to improvement of health and quality of life. The primary care clinician works at the front line where advances in genetic research can be directly applied to patient care.",
"   </p>",
"   <p>",
"    This review will focus on providing general guidelines related to genetic assessment for common, adult onset conditions and will address obtaining a health history, genetic counseling and testing, and the primary care clinician's role in this process. The genetics of specific disorders are addressed separately. A glossary of genetic terms is available in a table (",
"    <a class=\"graphic graphic_table graphicRef72267 \" href=\"UTD.htm?24/6/24685\">",
"     table 1",
"    </a>",
"    ) and, in an expanded form, in a separate topic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"     \"Glossary of genetic terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ROLE OF THE PRIMARY CARE OR REFERRING CLINICIAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care clinicians have multiple roles in assessing the genetic background of their patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obtaining the family history",
"     </li>",
"     <li>",
"      Assessing risk information",
"     </li>",
"     <li>",
"      Identifying and referring patients for whom a genetic consultation would be beneficial",
"     </li>",
"     <li>",
"      Coordinating long-term management for individuals who have hereditary syndromes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When a genetic referral is indicated, the referring provider should set patient expectations for the referral. Following the genetic consultation, when risk and genetic information from the consultant are available, the primary care clinician is generally responsible for long term follow-up. This may include overseeing behavioral modifications, interventions for disease prevention, or intensified screening for disease surveillance.",
"   </p>",
"   <p>",
"    Tools for the assessment of genetic risk include instruments to aid in obtaining a family history, medical records of family members, phenotypic measurements (eg, serum iron when hemochromatosis is a potential concern), and genetic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FAMILY HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in assessing inherited risk for many chronic conditions is collecting data related to the family history. The history is then reviewed for patterns consistent with various modes of inheritance.",
"   </p>",
"   <p>",
"    A 2009 panel sponsored by the National Institutes of Health evaluated evidence regarding the accuracy and effectiveness of obtaining a family history in the primary care setting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/4\">",
"     4",
"    </a>",
"    ]. The panel found that there is limited scientific evidence regarding how best to collect the history, the key elements of the history, the accuracy of reported history, or the impact of a positive family history on patient outcomes. While it is clear that more research in this field is indicated, and that the family history will not detect all families with inherited disorders, it remains a starting point for identifying appropriate candidates who could benefit from a genetic consultation.",
"   </p>",
"   <p>",
"    Although the family history is not highly predictive for common disease, it can help determine patients who are at average, moderate, or high risk for specific conditions, and can help to personalize health lifestyle messages [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Among 200 pedigrees from patients seen in a prenatal clinic, 5 to 15 percent were classified as moderate risk for at least one common adult condition and 1 to 10 percent were classified as high risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/7\">",
"     7",
"    </a>",
"    ]. Similar prevalence of high risk patients has been reported in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/8\">",
"     8",
"    </a>",
"    ]. Although moderate and high risk patients account for only a small portion of the patient population, these families represent a significant disease burden. As an example, a study in Utah found that while only 14 percent of the population had a positive family history for coronary heart disease, these families accounted for 48 percent of all the coronary heart disease in the state, and 72 percent of all early onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the potential significance of the family history, one study in community family medicine practices found that family histories were only discussed in 51 percent of new patient visits and 22 percent of follow-up visits [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/10\">",
"     10",
"    </a>",
"    ]. A study that surveyed community health center patients concluded that those who were more likely to talk with doctors as well as family members about their family health history were more likely to report a history of cancer or heart disease, opening the opportunity for clinicians to instigate a more comprehensive family history collection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/11\">",
"     11",
"    </a>",
"    ]. However, even when the family history is discussed, the level of detail and documentation of the history are often insufficient for making adequate risk assessments [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Collecting the information",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of obtaining a family history in the primary care setting is to identify diseases that are familial and patients who are appropriate candidates for referral to a genetic service for more thorough evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/3\">",
"     3",
"    </a>",
"    ]. It is not generally necessary to collect information beyond second degree relatives (eg, grandparents, aunts, uncles, first cousins, grandchildren); more complete pedigrees can be obtained by a genetic counselor when indicated. The patient should be aware that, for these purposes, concerns relate only to blood relatives, and not relatives through adoption or marriage.",
"   </p>",
"   <p>",
"    Although obtaining a detailed family history is often considered time consuming, a set of focused questions can yield important screening information. The American Academy of Family Physicians has developed the SCREEN mnemonic for obtaining a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       S",
"      </strong>",
"      ome",
"      <strong>",
"       C",
"      </strong>",
"      oncerns: Do you have any (some) concerns about diseases or conditions that seem to run in your family?",
"     </li>",
"     <li>",
"      <strong>",
"       R",
"      </strong>",
"      eproduction: Have there been any problems with pregnancy, infertility or birth defects in your family?",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      arly disease, death or disability: Have any members of your family been diagnosed with a chronic disease at an early age or have members of your family died at an early age?",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      thnicity: How would you describe your ethnicity? Or what country did your ancestors come from?",
"     </li>",
"     <li>",
"      <strong>",
"       N",
"      </strong>",
"      on-genetic conditions: Are you aware of any non-medical conditions or risk factors, like smoking or problem drinking that are present in your family?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional questions related to family size (\"How many brothers and sisters do you have?\"; \"Do you come from a large family?\") and consanguinity (\"Were your parents, or either set of grandparents, related to each other prior to marriage?\") are often helpful to interpret the responses to the screening questions.",
"   </p>",
"   <p>",
"    Patients may be unaware of precise medical diagnoses in family members, but can provide revealing information regarding symptoms and medication use. As well, patients may neglect to mention the medical conditions of siblings who have died (often the most informative information). Direct questions addressing these issues are also helpful.",
"   </p>",
"   <p>",
"    Several tools are also available to aid in the collection of family history information (",
"    <a class=\"graphic graphic_table graphicRef62528 \" href=\"UTD.htm?7/40/7820\">",
"     table 2",
"    </a>",
"    ). There is no evidence for the best way to obtain a family history in terms of instrument (using a form or interview) or format (open or closed questioning). Several institutions are developing and testing a variety of tools, especially those that integrate decision support for medical management and can be incorporated into an electronic medical record. While there are advantages to using a family health history, such as lower costs and easy acceptability, there are myriad challenges, and the utility as a public health tool is still to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When possible, patients should be encouraged to complete written or online family history questionnaires prior to their initial visit. Collecting the family history in advance of the visit allows patients to contact relatives and verify information. Clinicians can then efficiently review the information at the time of the visit. Both the maternal and the paternal history should be obtained.",
"   </p>",
"   <p>",
"    The family history should be clearly and completely documented in the medical record, whether collected during the session or as part of a patient-completed intake form. Appropriate documentation should include the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Condition(s) reported",
"     </li>",
"     <li>",
"      Relationship of affected individual to the patient",
"     </li>",
"     <li>",
"      Age of relative at onset of condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A useful method for documentation is a medical pedigree or family tree. The tree should be centered on the patient, and extend upward to include parents, aunts, uncles, and grandparents; laterally to include siblings and cousins; and downward to include children and grandchildren. Individuals are denoted with boxes (males), circles (females) or diamonds (unknown gender). A deceased individual is denoted by a strikethrough, and members who are affected by a specific condition are shown by shading. Current age (or age at death) and medical conditions are listed below each symbol. In families where more than one major medical condition is segregating, it is important to assure that shading is consistent for each condition and a legend is created to explain the shade marks. Alternately, it may be worthwhile to generate more than one pedigree (eg, one for cancer-related conditions, one for heart disease, etc.). An example of a four generation pedigree is provided (",
"    <a class=\"graphic graphic_figure graphicRef55908 \" href=\"UTD.htm?24/49/25374\">",
"     figure 1",
"    </a>",
"    ). Pedigree representation can be downloaded from resources such as",
"    <a class=\"external\" href=\"https://familyhistory.hhs.gov/\">",
"     My Family Health Portrait",
"    </a>",
"    and included in the medical record. Pedigrees typical of different Mendelian inheritance patterns are shown in several figures (",
"    <a class=\"graphic graphic_figure graphicRef75203 \" href=\"UTD.htm?10/45/10974\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65919 \" href=\"UTD.htm?17/32/17934\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56888 \" href=\"UTD.htm?12/46/13038\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The family history is dynamic and should be updated periodically and as needed as part of a diagnostic work-up. Follow-up visits should include questioning about recent deaths, births, or new diagnoses of significant conditions in family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     History obtained by a genetic counselor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The family history obtained by a genetic specialist is considerably more detailed than is feasible in the primary care setting. Estimates from medical genetic centers indicate that up to five hours may be spent collecting and verifying family history information [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/10,19\">",
"     10,19",
"    </a>",
"    ], although this is not typical. This level of detail and accuracy is sometimes necessary for making precise risk estimates, estimating the likelihood of genetic mutation, and making management recommendations.",
"   </p>",
"   <p>",
"    A family history taken by a genetic service is typically targeted to the condition of concern and goes back (and forward) at least three generations: the patient's parents, siblings and children; grandparents, grandchildren, aunts and uncles; nieces and nephews, grandchildren and first cousins. Information to be collected includes current age, health status, age at death and cause of death, and medical diagnoses with related environmental exposures.",
"   </p>",
"   <p>",
"    When a pattern of disease is noted, more focused questions are asked to assess for features of possible syndromes and direct the assessment. Medical record review of family members can confirm diagnoses when there is uncertainty or resolve inaccuracies if family members provide differing information [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/3,20\">",
"     3,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Interpreting the history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information in the family history should be evaluated for signs of inherited risk. When conditions are common in the general population, such as breast cancer (1 in 8 lifetime risk for women), or diabetes (1 in 6 individuals over the age of 60), clinicians will often encounter families with multiple affected relatives.",
"   </p>",
"   <p>",
"    Individuals can be classified into three risk categories (average, moderate, or high) for most common adult onset conditions. Criteria based on the family history have been proposed for categorizing an individual's risk for common diseases (",
"    <a class=\"graphic graphic_table graphicRef71096 \" href=\"UTD.htm?7/57/8091\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key factors that suggest that a genetic disorder is present include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple affected individuals in multiple generations from either side of the family",
"     </li>",
"     <li>",
"      Occurrence of the disease at an earlier age than usual",
"     </li>",
"     <li>",
"      Close degree of relatedness (ie, first degree or second degree relative) of affected relatives",
"     </li>",
"     <li>",
"      Presence of associated conditions in the family (eg, the association between breast and ovarian cancer or colorectal and endometrial cancer)",
"     </li>",
"     <li>",
"      Unusual presentations of common conditions (eg, bilateral disease in breast cancer, breast cancer in men)",
"     </li>",
"     <li>",
"      History of consanguinity (diseases caused by rare recessive mutations are more common in families with matings of related individuals). Consanguinity is generally more relevant to defining risk in the pediatric evaluation, than for conditions with adult onset.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additionally, the American Academy of Family Physicians has developed a table, based on the mnemonic GENES, for identifying red flags for hereditary conditions (",
"    <a class=\"graphic graphic_table graphicRef61908 \" href=\"UTD.htm?35/24/36235\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       G",
"      </strong>",
"      roup of congenital anomalies",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      xceptional presentation",
"     </li>",
"     <li>",
"      <strong>",
"       N",
"      </strong>",
"      eurodevelopmental delay",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      xtreme pathology",
"     </li>",
"     <li>",
"      <strong>",
"       S",
"      </strong>",
"      urprising laboratory values",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is most relevant for pediatric evaluations, but may be useful in adult onset conditions as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Patterns of inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history may display patterns consistent with a strong genetic influence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"     \"Overview of Mendelian inheritance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of the family history, referred to by geneticists as pedigree analysis, can suggest the mode of inheritance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal dominant disorders are associated with multiple generations of affected relatives, including both males and females (",
"      <a class=\"graphic graphic_figure graphicRef75203 \" href=\"UTD.htm?10/45/10974\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Autosomal recessive disorders show a pattern in which an individual's siblings are more likely to be affected than one's parents (",
"      <a class=\"graphic graphic_figure graphicRef65919 \" href=\"UTD.htm?17/32/17934\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      X-linked recessive disorders typically affect only males related to each other through their mothers. Male to male transmission is not observed (",
"      <a class=\"graphic graphic_figure graphicRef56888 \" href=\"UTD.htm?12/46/13038\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several limitations to relying on family history to identify high risk families. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small family size or gender underrepresentation &mdash; These factors may limit the ability to recognize patterns in the pedigree. As an example, small families or families with few women may fail to exhibit a strong pattern of breast and ovarian cancer even if a genetic mutation in the BRCA1 or BRCA2 genes is present [",
"      <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Uncertainty in parentage &mdash; Pedigrees will be inaccurate if parentage is incorrectly identified, or incomplete if parentage is not known. Population-based studies have found that up to 15 percent of subjects may misidentify parentage [",
"      <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disease prevention &mdash; Preventive practices (eg, removing premalignant polyps at colonoscopy, prophylactic oophorectomy, or treatment for high cholesterol levels) may prevent at risk relatives from presenting with the illness.",
"     </li>",
"     <li>",
"      De novo mutations and incomplete penetrance &mdash; Past generations will not display traits of de novo mutations. Incomplete penetrance can obscure the genetic pattern represented in pedigrees.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These limitations should be kept in mind when a patient presents with an unusual diagnosis, such as colon cancer at age 40, with a negative family history, and a genetic basis should not be ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR GENETIC SERVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling is not necessarily tied to genetic testing, although that tends to be an initial reason. Once an initial family history is collected, the individual's family history should be categorized as average, moderate, or high risk (",
"    <a class=\"graphic graphic_table graphicRef71096 \" href=\"UTD.htm?7/57/8091\">",
"     table 3",
"    </a>",
"    ). Individuals presenting with strong family histories for conditions with a known genetic basis should be offered genetic counseling. If genetic testing (ideally of an affected family member) identifies a mutation, other at-risk family members can be tested subsequently. For many conditions, specific screening and risk reduction strategies can be implemented for individuals at high risk.",
"   </p>",
"   <p>",
"    For a family with a strong history of conditions with less well defined genetic etiologies and currently no treatment options, such as asthma or Alzheimer disease, the value of genetic testing is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the absence of available genetic testing does not mean that a genetic risk assessment or counseling will not be worthwhile. The lack of complete understanding of the genetics of a condition does not preclude patients from having questions or concerns. For anxious families or individuals, a genetic consultation can provide education and counseling to help people understand and cope with risk information and make management decisions based on available options.",
"   </p>",
"   <p>",
"    Potential benefits to genetic counseling where genetic risk is uncertain include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals often have mistaken understanding of their risk of developing a disease; genetic counseling can help patients understand a more appropriate risk number and how to manage this information [",
"      <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Research or registry opportunities may exist that will allow early access to new genetic information and medical management or prevention opportunities for identified individuals or families [",
"      <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some families may choose to bank DNA for the possibility of future genetic testing even if a research registry is not available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Moderate risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals falling into the moderate risk category by family history (",
"    <a class=\"graphic graphic_table graphicRef71096 \" href=\"UTD.htm?7/57/8091\">",
"     table 3",
"    </a>",
"    ) often have a two- to three-fold increased risk for disease. The increased risk is most often due to a combination of lifestyle, environmental and low penetrance genetic factors that are shared within families.",
"   </p>",
"   <p>",
"    In general, a genetic evaluation is not necessary for individuals who fall into the moderate risk range, unless the family is particularly anxious. However, it remains important for the clinician to take a moderate family history into account when planning care. For example, a patient whose father had colon cancer at age 55 would fall into the moderate risk category, with an estimated two-fold increased risk for colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Colonoscopy for this patient would be recommended at age 40 rather than the usual 50 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     High risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic contribution to risk for individuals in the high risk category is strong, and these individuals may have a 50 percent or greater lifetime risk for being affected. For inheritable conditions that are subject to population-based screening (eg, colorectal cancer or breast cancer), onset of the condition in high risk families often occurs at an earlier age than screening onset recommended for the general population.",
"   </p>",
"   <p>",
"    Patients classified as high risk are appropriate candidates for a full genetic evaluation. However, even when high risk families are identified, referrals for genetic services are often not made. A study of 387 consecutive patients seen in a gastroenterology practice at an academic medical center found that only 17 percent of those reporting a family history meeting guidelines for evaluation for Lynch syndrome were referred for genetic services [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barriers to referral may include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perceived lack of benefit from genetic information",
"     </li>",
"     <li>",
"      Uncertainty about how to incorporate genetic information into clinical management",
"     </li>",
"     <li>",
"      Lack of clinician awareness that a cluster of diverse cancers may relate to a genetic condition",
"     </li>",
"     <li>",
"      Lack of awareness of the availability of genetic tests or genetic counselors",
"     </li>",
"     <li>",
"      Patient reluctance to undergo genetic assessment",
"     </li>",
"     <li>",
"      Fear that something harmful will be found",
"     </li>",
"     <li>",
"      Cost and reimbursement issues",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Uncertainty about genetic basis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians may be uncertain whether there is sufficient information about the genetic etiology of a condition for a referral to be useful. The rapid rate of gene discovery following the mapping of the genome and the advent of genome-wide association studies makes it challenging to keep informed.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://ncbi.nlm.nih.gov/sites/GeneTests/\">",
"     GeneTests website",
"    </a>",
"    is a publicly funded medical genetic information resource that lists available genetic tests for thousands of conditions, with a directory of certified clinical laboratories specializing in genetic testing. As of January 2012, the site lists over 2500 diseases for which a genetic basis has been established and for which clinical genetic testing is available. This number represents a doubling of tests that were available in 2002. This rapid rate of expansion of clinical genetic information is anticipated to continue for the foreseeable future. In 2012, the laboratory information contained in GeneTests will migrate to a new NIH-supported website,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/gtr/\">",
"     Genetic Testing Registry",
"    </a>",
"    (GTR). There are plans for at least one year of overlap of the GeneTests website and the GTR, and it is likely that the GeneTest website will point to GTR by October 2012 at the latest. When considering a possible genetic basis of disease, clinicians are encouraged to consult the GeneTests website.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONTENT OF GENETIC COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As defined by the National Society of Genetic Counselors, genetic counseling is the process of helping people understand and adapt to the medical, psychological and familial implications of genetic contributions to disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/30\">",
"     30",
"    </a>",
"    ]. This process integrates the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interpretation of family and medical histories to assess the chance of disease occurrence or recurrence.",
"     </li>",
"     <li>",
"      Education about inheritance, testing, management, prevention, resources and research.",
"     </li>",
"     <li>",
"      Counseling to promote informed choices and adaptation to the risk or condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The process of genetic counseling is about sharing information. It involves obtaining the family history and medical information from the patient and referring clinician, obtaining and reviewing medical records (of the patient and family members) to resolve uncertainties, understanding the patient's perception of risk of developing the condition, and his or her perspective on obtaining more certain information. The genetic counselor then formulates and presents a risk assessment that includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What genetic testing is available and what test results may mean for the patient",
"     </li>",
"     <li>",
"      How to modify that risk, if possible",
"     </li>",
"     <li>",
"      How to deal with the information as it pertains to medical management, emotional response, and family dynamics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of genetic consultations take place over one to three visits. Most initial genetic consultations are provided in person. Some centers may provide genetic test results by telephone or other service delivery models, such as televideo.",
"   </p>",
"   <p>",
"    The initial visit focuses on reviewing information and providing risk assessment. Many centers also obtain information about the psychosocial impact of the condition on the family, with particular regard to experiences in caregiver roles or early deaths. When appropriate, the option of genetic testing is discussed.",
"   </p>",
"   <p>",
"    If genetic testing is pursued, there will usually be a follow-up visit or telephone call to discuss results and management implications. Additional follow-up visits may be scheduled to assist the patient in better understanding the implications of the result and help to make management decisions. For patients who are not appropriate candidates for genetic testing, or who elect not to be tested, risk estimates and management recommendations will be made on the basis of personal and family history.",
"   </p>",
"   <p>",
"    Most genetic services are in the form of consultations to the primary care provider. Unless incorporated into a multidisciplinary high risk clinic, genetic services usually do not directly offer screening and management services. Typically, patients will be referred back to their physicians, with recommendations for their follow-up care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Preparation for referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;To alleviate patient anxiety and better prepare the patient (for example, if additional family health history is useful), the primary care clinician needs to discuss with the patient that the referral is being made, describe what features in the family prompted the referral, and provide a description of what the visit will entail [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Where to refer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://ncbi.nlm.nih.gov/sites/GeneTests/\">",
"     GeneTests website",
"    </a>",
"    provides an international listing of clinics (by state, for the United States) that identifies counseling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diagnostic testing services for specified types of services, including adult genetics, biochemical genetics, cancer genetic risk assessment, pediatric genetics, preimplantation diagnosis, prenatal diagnosis, and telemedicine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the first session, if sufficient information is available, a risk assessment is performed. Several models, some based on empiric data and others based on computer algorithms, can be used to determine risk of developing the condition or risk of having a particular mutation. These models are relatively well developed for many cancer syndromes (including breast, ovarian, and colorectal) and are being evaluated for cardiovascular, asthma, diabetes and some neurological diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2872?source=see_link\">",
"     \"Risk prediction models for breast cancer screening\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once an objective risk figure has been determined, it is important to correlate this with the patient's belief of his or her risk. The patient's personal experience with affected family members may significantly impact his or her perception of personal risk. When the patient's beliefs are not concordant with the calculated risk, the primary care provider and genetic counselor need to provide ongoing communication and counseling to help the patient understand the implications of the risk figure.",
"   </p>",
"   <p>",
"    The initial risk figure is subject to modification. Risk may be modified by additional family history information, lifestyle changes or medications that increase decrease risk for particular conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link\">",
"     \"Cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening is a means of early disease detection and does not modify the risk, but can modify treatment options and the course of the disease if the condition is identified at an early stage. More aggressive screening (earlier, more frequent, other modalities) may be indicated for targeted conditions. As an example, for patients with familial adenomatous polyposis, screening colonoscopy is recommended to begin at age 10 to 12. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Information to send with the referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a decision is made to refer a patient to a genetic counselor, the referring clinician should provide the following information to the consultant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific questions to be addressed by the referral. As an example, \"This patient is at high risk for breast cancer due to her family history that includes both thyroid cancer and early onset breast cancer. What testing is recommended for her?\"",
"     </li>",
"     <li>",
"      A summary of available family history information, either in a table or pedigree format, including affected family members up to two generations removed from patient, indicating their age at diagnosis and current age.",
"     </li>",
"     <li>",
"      A summary of the patient's pertinent medical history, including laboratory test results or biopsy reports, where relevant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing for adult onset conditions serves two principal purposes: to confirm or establish a diagnosis, or to assess risk for asymptomatic patients.",
"   </p>",
"   <p>",
"    Knowledge of an increased risk for a particular disease may lead to changes in patient behavior or clinical interventions to decrease the risk. Management strategies to decrease risk range from increased sun protection, to enhanced screening, to risk-reducing surgery or chemoprophylaxis, with varying levels of effectiveness in improving outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link\">",
"     \"Cancer prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link\">",
"     \"Chemoprevention strategies in prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=see_link\">",
"     \"Primary prevention of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic testing for germline mutations can be conducted on virtually any tissue. Most laboratories prefer blood specimens, although cheek (buccal) swabs also transport well and are an efficient way to obtain DNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Purpose of genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing can be done for diagnostic or predictive purposes. Additionally, testing can be performed at different times during a lifespan including preimplantation testing, prenatal screening and testing, newborn screening, and testing at some point after birth to establish a diagnosis, determine carrier status (for autosomal recessive conditions) or for predictive purposes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preimplantation testing &mdash; Preimplantation testing, for high risk couples, is performed on embryos resulting from in vitro fertilization. Identification of chromosomal or molecular abnormalities allows selection of unaffected embryos to implant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"       \"Preimplantation genetic diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prenatal testing &mdash; Prenatal testing identifies conditions in which a mutation has been identified in a parent. Typically, the gene being analyzed is inherited in an autosomal dominant manner, so each fetus has an a priori risk of 50 percent of inheriting the mutation. Specimens for analysis are obtained either by chorionic villus sampling or amniocentesis.",
"      <br/>",
"      <br/>",
"      The goals of prenatal counseling and testing are to provide reassurance or guide and support decisions regarding whether to continue or terminate a pregnancy that may result in an affected individual. Prenatal testing for a condition such as Huntington disease, which is fully penetrant, carries different implications than testing for a condition that confers an increased risk of developing the disease, such as colon cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=see_link\">",
"       \"Basic principles of genetic counseling for the obstetrical provider\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diagnostic testing &mdash; Diagnostic genetic testing is used to support a specific diagnosis in a patient with an existing condition. There are over 2500 conditions for which genetic testing can be offered. Most of these conditions are relatively rare and manifest shortly after birth or in childhood. Some, such as Huntington disease, do not manifest until later in life, at which time genetic testing would also be appropriate.",
"      <br/>",
"      <br/>",
"      Another example of diagnostic testing is offering full sequence analysis of the BRCA1 and BRCA2 genes to a 32-year-old woman recently diagnosed with breast cancer who wants to make surgical decisions. Diagnostic testing of an individual with multiple polyps can distinguish between Lynch syndrome and attenuated familial adenomatous polyposis, and therefore provide information regarding extracolonic risks.",
"     </li>",
"     <li>",
"      Predictive testing &mdash; Predictive testing is a method of risk assessment for unaffected individuals who are at risk for developing conditions with a hereditable component. The value of a gene test is influenced by the penetrance of the gene (whether the presence of a gene makes it highly likely that the person will develop the related phenotype) and whether there are effective prevention or early treatment strategies to impact the course of the condition. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Penetrance, ascertainment bias, and variable expression'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H21\">",
"       'Validity and utility'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Carrier testing &mdash; Carrier testing is used to identify asymptomatic individuals who are heterozygous (ie, carry one copy of a gene) for a mutation that causes a genetic disorder in homozygotes (individuals who carry two copies). Carrier testing can be performed in families with a family history for a specific genetic condition, or in particular ethnic groups or populations in which risk mutations are at relatively high prevalence (eg, Tay Sachs screening among Ashkenazi Jews). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=see_link\">",
"       \"Prenatal screening for genetic disease in the Ashkenazi Jewish population\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Penetrance, ascertainment bias, and variable expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of a positive genetic test can be limited by the lack of population-based data on penetrance (likelihood of developing disease given inheritance of a disease-causing mutation) and variable expressivity (phenotypic variations in the way the disease is expressed).",
"   </p>",
"   <p>",
"    Genetic mutations are initially studied in high-risk families identified because of their high expression of disease (ie, high penetrance). This practice overestimates the penetrance that later is found in more population-based studies. As an example, while high-risk families with a genetic mutation in BRCA1 show an 85 percent lifetime risk of developing breast cancer, population-based studies report a 57 percent lifetime risk of developing cancer in individuals with this mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Cancer risk in some individuals with a BRCA1 mutation may be further decreased as they seek more aggressive interventions, such a risk-reducing surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/2,32-39\">",
"     2,32-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ascertainment bias is reflected not only in disease penetrance, but also in variability in the expressivity of a condition. Initial discovery of mutations often derives from high risk families with prominent impact of the disease. For example, in the original research studies, families eligible to be considered for Lynch syndrome were defined by the Amsterdam criteria that required three or more affected individuals, including two who were closely related, and one with colon cancer under the age of 50. When a population based sample of colon cancer patients was evaluated for Lynch syndrome, however, only 13 percent of mutation carriers met these criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variable expressivity of the genotype will result in a wide range of severity, age of onset, or progression of disease. Some people with two HFE mutations (causing hemochromatosis), for example, do not go on to develop the complications of iron overload, even in the absence of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimates of risk based upon high-risk populations are greater than the risk estimated in those identified by population-based screening. When providing risk information, the literature should be reviewed to find the studies conducted with participants that most closely match a patient's situation. In many cases, patients will need to be presented with a potential range of risk estimates and an explanation of the reason for this range.",
"   </p>",
"   <p>",
"    Screening and management options for identified mutations have often been developed for high-risk families. The efficacy of these therapies for individuals at lower risk may be unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/39\">",
"     39",
"    </a>",
"    ]. Genetic consultation can play an important role to assure that highest-risk individuals benefit from appropriate management, while lower risk individuals not receive unnecessary intervention in the absence of applicable evidence for improved outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Validity and utility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical validity refers to the ability of a genetic test to predict a disease phenotype. For some tests, such as familial adenomatous polyposis, the clinical validity is very high. Virtually all individuals who test positive for a mutation in the APC gene will develop features of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/43\">",
"     43",
"    </a>",
"    ]. In contrast, individuals who test positive for the APOE",
"    <span class=\"nowrap\">",
"     e4/e4",
"    </span>",
"    genotype have approximately a 30 percent chance of developing Alzheimer's disease, and most individuals with this genotype will not develop the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical utility of a genetic test refers to the impact of the testing information on clinical care. While the genetic test for Huntington has high clinical validity, the clinical utility is limited because of few treatment or intervention options available for those who test positive. However, family members at risk for this disease may choose to undergo gene testing to make reproductive plans or for the psychological benefit in relieving uncertainty and facilitating future planning [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determining the clinical utility involves considering the severity of the disease, the options for management, and the likelihood that genetic testing will change the course of treatment. The CDC provides an",
"    <a class=\"external\" href=\"file://www.cdc.gov/genomics/gtesting/ACCE/acce_proj.htm#T1\">",
"     online resource",
"    </a>",
"    with a list of questions to ask in order to assess the clinical validity and utility of a genetic testing (",
"    <a class=\"graphic graphic_table graphicRef68534 \" href=\"UTD.htm?3/15/3326\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ethical, legal, and psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians must consider the benefits and risks of genetic testing including the possibility of false positive and false negative results. Genetic information may have unique risks based upon the meaning attributed to a disorder being genetic and the value of the information for family members [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the familial nature of genetics, the psychosocial issues require not just an understanding of the patient, but of the dynamics of the patient's family. Many genetic counselors use the family history intake to assess the family dynamics and more recently, to incorporate outside influences that impact the social support of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient autonomy is a central tenet in genetic counseling, and assuring that the patient has sufficient support to make decisions is vital. This is encouraged by providing accurate and appropriate information in an empathic environment with professional guidance. Understanding the potential responses to difficult or unexpected news and being able to respond in a productive manner is essential to long-term acceptance of genetic information and management options.",
"   </p>",
"   <p>",
"    In the absence of proven beneficial interventions, the value of genetic testing for an individual may be the relief derived when a test is negative in the face of a known mutation in an affected family member. On the other hand, some patients receiving negative results experience \"survivor guilt\" if other family members are found to have the mutation. Family dynamics can be affected. As an example, some family members found not to have the gene mutation or Huntington's disease may be rejected by affected family members due to the loss of a common risk status [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Genetic discrimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have expressed concern about the potential for loss of health insurance or employment opportunities as a result of genetic testing. This is particularly true for the unaffected individual and their unaffected extended family members [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, legal protection against the use of genetic information by group health insurance plans is available at the federal level through the Genetic Information Nondiscrimination Act (GINA) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/54\">",
"     54",
"    </a>",
"    ]. Enacted in 2008, GINA prohibits discrimination by health insurers and employers on the basis of genetic information. Most states also have additional legislation protecting against the use of genetic information by health insurers and employers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/47,55\">",
"     47,55",
"    </a>",
"    ]. Because of these legal protections, the concern for genetic discrimination may decrease and genetic testing may become more widespread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Disclosure to family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic risk, whether assessed by genetic testing or family history, raises the potential ethical or legal obligation of a physician to disclose genetic information to other at risk family members. Most patients are willing to provide consent for such disclosure, or readily do it themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. For some, their express purpose for genetic testing is to make information available to family members.",
"   </p>",
"   <p>",
"    However, a patient's refusal to voluntarily disclose raises difficult conflict between two competing ethical obligations: the duty to protect patient privacy and autonomy versus the duty to disclose for the purpose of preventing future harm. Legal opinions vary regarding the physician's duty to warn at-risk family members about a familial genetic condition. In the limited number of cases involving genetic information, the courts have affirmed a physician's legal responsibility to warn family members [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/58\">",
"     58",
"    </a>",
"    ]. Despite numerous guidelines and policy papers, there is currently no clear consensus or set of legal guidelines available in most countries. Until such time as clear legal obligations are defined, physicians should consult with medical geneticists, genetic counselors, or bioethicists in the event that patients do not provide consent to share information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Gene test uptake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geneticists refer to the percentage of patients who obtain a test when it is offered as uptake, especially when offering a genetic test to an otherwise healthy individual. The above factors (penetrance, utility, ethical issues) are some of the reasons why there is varied use of DNA predictive testing for different condition by patients. Other reasons include a sense that the test is not urgent or the risk perception is not significant enough to warrant testing. Finally, finances play a role in predictive genetic testing uptake, as insurance companies vary in their reimbursement policies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is currently available for over 2500 conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/59\">",
"     59",
"    </a>",
"    ]. An overview of genetic testing and specifics of available genetic tests is available online at",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/\">",
"     GeneTests",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Whom to test",
"    </span>",
"    &nbsp;&mdash;&nbsp;When possible, molecular genetic testing should initially be performed on an affected family member. For ethical reasons, genetic testing for conditions that most commonly manifest in adults is generally not done in children and adolescents unless a preventive intervention is effective only if done during those time periods.",
"   </p>",
"   <p>",
"    Genetic testing of an affected individual is usually important to facilitate interpretation of testing in other family members. Once a particular mutation has been identified, testing other family members is technically straightforward. While it is possible to begin the genetic testing process in an unaffected individual, there is a greater chance that these results will be inconclusive. As an example, if an unaffected person does not have a mutation in a particular gene, is it because that gene is not mutated in the family, or because the mutation does exist in the family and the unaffected person did not inherit it?",
"   </p>",
"   <p>",
"    In some cases the affected family members are deceased or unable or unwilling to participate. Genetic counseling in these situations should evaluate the optimal testing approach in the family, facilitate family communication, and explain the limitations of genetic testing when it cannot be performed on the ideal candidate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Informed consent for testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent, a tenet of patient-centered medicine, is a foundation for the voluntary nature of genetic testing. Informed consent means that the patient understands and agrees to the procedure. When offering genetic testing, especially to unaffected individuals, most clinicians follow language from the Department of Health, Education, and Welfare which encourages that the patient is able to voluntarily exercise free power of choice, without any element of force, fraud, deceit, duress, over-reaching, or other ulterior form of constraint or coercion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consent, therefore, involves discussion, and not just the signing of a document. Discussion should include the procedure; the risks, benefits and limitations; the potential results; and the management options that can be available based on the result.",
"   </p>",
"   <p>",
"    Two exceptions exist to the general suggestion to obtain informed consent for genetic testing. Newborn screening in the United States does not involve active consent, but parents who do not want their child tested can sign a form that indicates their refusal. Additionally, in some clinical pediatric circumstances, genetic testing is considered part of the diagnostic evaluation, so less of an effort may be made to obtain fully informed consent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Samples for testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many techniques for genetic testing, and the best approach depends on the gene to be evaluated. Testing may be DNA-based, cytogenetic, or metabolic, depending upon its purpose (",
"    <a class=\"graphic graphic_table graphicRef63290 \" href=\"UTD.htm?39/19/40252\">",
"     table 6",
"    </a>",
"    ). The methods for obtaining the specimen (cheek swab, blood or tissue sample), the costs (ranging from less than $100 to greater than $4000), and the waiting time for results (ranging from days to weeks) differ according to the test involved.",
"   </p>",
"   <p>",
"    For some conditions, such as thrombophilias or hemochromatosis, testing may involve analysis of clotting factors or serum iron levels, rather than direct DNA analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Insurance reimbursement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, insurance reimbursement is becoming more common for genetic testing, as testing becomes a more routine part of clinical care. Coverage of genetic testing by insurance will vary depending on the type of test, whether it is being done to make a diagnosis in an affected person or to predict risk in an unaffected individual, and on the patient's specific type of insurance coverage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Where to test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some genetic testing for common conditions such as Factor V Leiden are common and offered through many laboratories, while other genetic tests are more specialized and may only be available from one or two laboratories.",
"   </p>",
"   <p>",
"    In some cases, testing is only available in a research setting. Most research laboratories are not CLIA certified and not authorized to provide results back for the purpose of clinical decision making. Therefore, when pursuing testing through a research study, it is important to clarify with the investigator the exact testing that will be done on the sample, if and how results might become available, and the expected turnaround time.",
"   </p>",
"   <p>",
"    For conditions in which genes have not yet been identified or there is a lack of evidence of an effective intervention, preservation of genetic material from the affected individual by DNA banking for future genetic testing is a reasonable option. This involves the storage of DNA material (usually blood but occasionally tissue samples) for future testing should it become desired. Local laboratory specific information on DNA banking is available through",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/\">",
"     GeneTests",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, there are several laboratories that offer this service direct to the consumer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Outcomes of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are typically three outcomes from genetic testing: the causative mutation may be identified; no mutation is identified, or a variant of uncertain significance is identified.",
"   </p>",
"   <p>",
"    Finding a causative mutation can confirm a diagnosis in the affected person. Clarification of the genetic etiology of the proband's disease may aid in planning treatment or in predicting the risks for other health problems. Identification of a mutation also allows for predictive genetic testing to be offered to at-risk family members.",
"   </p>",
"   <p>",
"    Once a mutation has been identified, other family members can usually be tested for the specific genetic alteration with close to 100 percent accuracy. The cost of genetic testing is often reduced once the specific genetic mutation has been identified. Those family members who have inherited the genetic mutation may be candidates for enhanced screening or risk reduction strategies, while those who have not inherited the alteration can be spared unnecessary procedures.",
"   </p>",
"   <p>",
"    An inherited risk is not ruled out when a genetic mutation is not identified. A negative result may mean that the genetic cause cannot be identified with current technologies. The sensitivity of genetic testing varies, with tests for Huntington's disease and factor V Leiden having a sensitivity greater than 99 percent, while tests for other syndromes such as Marfan syndrome have only a 70 percent sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. For many conditions, only some of the contributing genetic factors have been identified. Mutations in the CDKN2A gene, for example, account for 20 to 40 percent of families with hereditary melanoma, suggesting that there are likely other loci that are contributing to risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determining whether a particular variant disrupts the function of the gene and is related to risk for disease, or is an alternative polymorphic form of the gene with no clinical implications, can be difficult. When variants of uncertain significance are identified, risk estimates should be made on the basis of the family history. An inherited risk should neither be ruled out nor in on the basis of this uncertain finding. It is also important to let the family know that most laboratories continue to research variants of uncertain significance, and in some cases, they can be reclassified. Having a plan in place to communicate with the individual or family can be important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Genome screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole genome sequencing and genotyping are beginning to change the paradigm of genetic testing. These technologies can provide information about the risks for many different diseases, and these tests are also being marketed directly to consumers.",
"   </p>",
"   <p>",
"    Whole genome and exome sequencing strategies have been used on a research basis to successfully identify the genetic basis of several rare diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. However, little is known about the utility of incorporating whole genome or exome data into clinical care. The ClinSeq project, sponsored by the NIH, is the first large-scale study using whole genome sequencing and returning results to participants [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/68\">",
"     68",
"    </a>",
"    ]. This study has identified several challenges that will need to be addressed before this technology can be incorporated into clinical care.",
"   </p>",
"   <p>",
"    Whole genome or exome sequencing requires substantial informatics resources and expertise to analyze the billions of nucleotides to identify genetic variants that will have clinical relevance. Also many genetic variants identified through this technology will be unclassified, so their affect on gene function is unknown. Finally, the process for consenting patients for this type of testing will be different than testing targeted for a known condition. Traditionally genetic testing is ordered when there is a suspicion that a person may have a genetic condition or if a condition is known in the family. The testing is targeted and will only provide information about the likelihood of that specific condition. However, more extensive gene analysis has the potential for a much wider range of findings, including carrier status for rare recessive disease that may impact reproductive decision making, genetic predisposition to diseases for which there are actionable steps for reducing risk, and genetic predisposition for disease for which there are no known approaches for modifying risk as well as potential pharmacogenetic interactions. Additional research is needed to determine how to appropriately consent individuals for this type of testing and how to return information in a meaningful way.",
"   </p>",
"   <p>",
"    Patients will need to be informed about the variety of information that may be come from this type of testing and novel counseling approaches will need to be developed to convey this vast range of information to patients effectively and efficiently. Despite the potential changes, the research in this area has found a high level of interest in this testing, mostly among a highly-educated population. Motivations for testing include a desire to help forward research and to learn more about the genetic factors that may be contributing to one&rsquo;s risk for disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genomic testing, which involves looking for single-nucleotide polymorphisms (SNPs) that have been found to be associated with a risk for disease, are more widely available than whole genome sequencing. Several companies are offering SNP-based genomic testing directly to consumers as well as medical practitioners. While the technology to efficiently and accurately identify these genetic variants is well established, many questions remain regarding the calculation of risk based on these SNPs. One study has evaluated genotype-panel based testing from two companies highlights the uncertainty regarding the value of these tests [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/70\">",
"     70",
"    </a>",
"    ]. DNA from five subjects was sent to each company for testing. While the information reporting the genetic code was concordant for more than 99 percent of markers tested, the risk prediction was concordant across all five subjects for only 4 of 13 conditions. Another study compared family history&ndash;based risk assessment to SNP-based testing for breast, prostate, and colon cancer risk assessment. Family history&ndash;based assessment classified 22 of 88 participants as high risk, while SNP-based testing only identified one high-risk patient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/71\">",
"     71",
"    </a>",
"    ]. Thus, while generating such information is technically feasible, using the data to accurately predict disease risk is problematic at this time.",
"   </p>",
"   <p>",
"    The primary care clinician will be an important link between genomic testing and the patient. As this testing becomes more widespread, especially in regard to pharmacogenomic components, patients will be more likely to ask physicians for help in interpreting test results. The challenge will be to determine how molecular findings will be integrated with the assessment of the family history to develop a management plan [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     MANAGEMENT AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term management of patients who have an inherited risk for disease may involve more aggressive screening initiated at an earlier age than in the general population, counseling for lifestyle modifications, initiation of pharmacologic or surgical interventions, and management of related psychosocial issues.",
"   </p>",
"   <p>",
"    The primary care clinician will play a crucial role in helping patients adhere to guidelines over the long-term and in coordinating care between multiple specialists. Many genetic conditions are associated with multiple risks. For example, individuals with Lynch syndrome have an increased risk for multiple cancers and will need appropriate screening for cancers not present in the proband family member [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=see_link\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While informing a patient about the risks to one's relatives may be sufficient to satisfy the physician's duty for family disclosure, this may not be sufficient to prepare the patient to take appropriate action. Genetic services often provide patients with written materials to facilitate the sharing of information. Primary care physicians can help play a role in checking in with patients to see how the information is flowing through the family and identifying possible communication barriers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/1/24602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The field of genetics is rapidly evolving. A number of online resources are available to help practitioners obtain up-to-date information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GeneTests (",
"      <a class=\"external\" href=\"file://www.genetests.org\">",
"       www.genetests.org",
"      </a>",
"      ) &mdash; directories of genetic clinics and laboratories; GeneReviews: overviews and disease-specific discussions of counseling, diagnosis and management for individuals and families with inherited disorders",
"     </li>",
"     <li>",
"      National Cancer Institute (",
"      <a class=\"external\" href=\"file://www.cancer.gov/cancerinfo\">",
"       www.cancer.gov/cancerinfo",
"      </a>",
"      ) &mdash; Genetic components of cancer including evidence based overview to clinical genetics (PDQ)",
"     </li>",
"     <li>",
"      The Human Genome Epidemiology Network (HuGE Net) (",
"      <a class=\"external\" href=\"file://www.cdc.gov/genomics/hugenet/default.htm\">",
"       www.cdc.gov/genomics/hugenet/default.htm",
"      </a>",
"      ) &mdash; Epidemiology and public health aspects of genetics",
"     </li>",
"     <li>",
"      National Society of Genetic Counselors (",
"      <a class=\"external\" href=\"file://www.nsgc.org\">",
"       www.nsgc.org",
"      </a>",
"      ) &mdash; The website will provide information regarding how to find a counselor as well as consumer information regarding developing a family history, and what to expect from a genetic consultation.",
"     </li>",
"     <li>",
"      Online Mendelian Inheritance in Man (",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM\">",
"       www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM",
"      </a>",
"      ) &mdash; Catalog of human genetic disorders",
"     </li>",
"     <li>",
"      Kansas University Medical Center (",
"      <a class=\"external\" href=\"file://www.kumc.edu/gec/geneinfo.html\">",
"       www.kumc.edu/gec/geneinfo.html",
"      </a>",
"      ) &mdash; Educational and clinical information on genetics; links to many helpful web sites on genetics including those listed here",
"     </li>",
"     <li>",
"      Genetic Science Learning Center (",
"      <a class=\"external\" href=\"file://learn.genetics.utah.edu/\">",
"       file://learn.genetics.utah.edu/",
"      </a>",
"      ) &mdash; Educational and clinical information about genetics and genetic conditions; links to many helpful web sites about genetics; exercises for teaching genetics from classroom to the clinic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary care clinicians work on the front line where advances in genetic research can be directly applied to patient care. Their role, in terms of genetic counseling, is to obtain the family history, identify high-risk individuals, refer appropriate patients for genetic services, and coordinate long-term management. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Role of the primary care or referring clinician'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the family history is not a highly-predictive measure for many common diseases, it can help determine which patients are at average, moderate, or high risk for specific conditions. Key questions to ask in obtaining a family history relate to patient concerns about disease, problems with pregnancy or birth defects in the family, early deaths or disease onset, ethnicity, and determination of nongenetic risk factors for disease. Patients should be encouraged to complete written or online family history questionnaires prior to their initial visit. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Family history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients classified as high risk are appropriate candidates for a full genetic evaluation. Individuals falling into the moderate risk category by family history generally may not require formal genetic evaluation. They often have a two- to threefold increased risk for disease related to a combination of lifestyle, environmental, and low-penetrance genetic factors that are shared within families. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for genetic services'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests\">",
"       GeneTests website",
"      </a>",
"      lists available genetic tests and is updated regularly. In 2012, the laboratory information contained in GeneTests will migrate to a new NIH-supported website,",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/gtr/\">",
"       Genetic Testing Registry",
"      </a>",
"      (GTR). There are plans for at least one year of overlap of the GeneTests website and the GTR, and it is likely that the GeneTest website will point to GTR by October 2012 at the latest. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for genetic services'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing can be done for diagnostic or predictive purposes. Additionally, testing can be done to determine carrier states, as well as for prenatal testing, preimplantation testing, and newborn screening. The predictive value of a positive genetic test is limited by variable penetrance and expression. The clinical utility of a genetic test refers to the impact of the testing information on clinical care. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Principles of genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ethical, legal, and psychosocial impacts of genetic testing must be taken into consideration. The 2008 Genetic Information Nondiscrimination Act (GINA) prohibits heath insurance and employment discrimination of unaffected individuals based on genetic information in the United States. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Ethical, legal, and psychosocial issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing of an affected individual is usually important to facilitate interpretation of testing in other family members. Once a particular mutation has been identified, testing other family members is technically straightforward. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long-term management of patients who have an inherited risk for disease may involve more aggressive screening initiated at an earlier age than in the general population, counseling for lifestyle modifications, initiation of pharmacologic or interventional preventive measures, and management of related psychosocial issues. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Management and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/1\">",
"      Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008; 299:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/2\">",
"      Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/3\">",
"      Guttmacher AE, Porteous ME, McInerney JD. Educating health-care professionals about genetics and genomics. Nat Rev Genet 2007; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/4\">",
"      Berg AO, Baird MA, Botkin JR, et al. National Institutes of Health State-of-the-Science Conference Statement: Family History and Improving Health. Ann Intern Med 2009; 151:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/5\">",
"      Wilson BJ, Qureshi N, Santaguida P, et al. Systematic review: family history in risk assessment for common diseases. Ann Intern Med 2009; 151:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/6\">",
"      Claassen L, Henneman L, Janssens AC, et al. Using family history information to promote healthy lifestyles and prevent diseases; a discussion of the evidence. BMC Public Health 2010; 10:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/7\">",
"      Scheuner MT, Wang SJ, Raffel LJ, et al. Family history: a comprehensive genetic risk assessment method for the chronic conditions of adulthood. Am J Med Genet 1997; 71:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/8\">",
"      Frezzo TM, Rubinstein WS, Dunham D, Ormond KE. The genetic family history as a risk assessment tool in internal medicine. Genet Med 2003; 5:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/9\">",
"      Hunt SC, Gwinn M, Adams TD. Family history assessment: strategies for prevention of cardiovascular disease. Am J Prev Med 2003; 24:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/10\">",
"      Medalie JH, Zyzanski SJ, Langa D, Stange KC. The family in family practice: is it a reality? J Fam Pract 1998; 46:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/11\">",
"      Kaphingst KA, Goodman M, Pandya C, et al. Factors affecting frequency of communication about family health history with family members and doctors in a medically underserved population. Patient Educ Couns 2012; 88:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/12\">",
"      Grover S, Stoffel EM, Bussone L, et al. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2004; 2:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/13\">",
"      Tyler CV Jr, Snyder CW. Cancer risk assessment: examining the family physician's role. J Am Board Fam Med 2006; 19:468.",
"     </a>",
"    </li>",
"    <li>",
"     SCREEN: Taking a Family for Familial Disease. Available at: file://www.aafp.org (Accessed on July 30, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/15\">",
"      Hulse NC, Ranade-Kharkar P, Post H, et al. Development and early usage patterns of a consumer-facing family health history tool. AMIA Annu Symp Proc 2011; 2011:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/16\">",
"      Valdez R, Yoon PW, Qureshi N, et al. Family history in public health practice: a genomic tool for disease prevention and health promotion. Annu Rev Public Health 2010; 31:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/17\">",
"      Scheuner MT, de Vries H, Kim B, et al. Are electronic health records ready for genomic medicine? Genet Med 2009; 11:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/18\">",
"      Feero WG, Bigley MB, Brinner KM, Family Health History Multi-Stakeholder Workgroup of the American Health Information Community. New standards and enhanced utility for family health history information in the electronic health record: an update from the American Health Information Community's Family Health History Multi-Stakeholder Workgroup. J Am Med Inform Assoc 2008; 15:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/19\">",
"      Bernhardt BA, Pyeritz RE. The economics of clinical genetics services. III. Cognitive genetics services are not self-supporting. Am J Hum Genet 1989; 44:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/20\">",
"      Mouchawar J, Laurion S, Ritzwoller DP, et al. Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: reactions from women and their physicians in a managed care organization. Am J Manag Care 2005; 11:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/21\">",
"      Whelan AJ, Ball S, Best L, et al. Genetic red flags: clues to thinking genetically in primary care practice. Prim Care 2004; 31:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/22\">",
"      Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007; 297:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/23\">",
"      Bellis MA, Hughes K, Hughes S, Ashton JR. Measuring paternal discrepancy and its public health consequences. J Epidemiol Community Health 2005; 59:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/24\">",
"      Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. JAMA 1995; 274:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/25\">",
"      Pilarski R. Risk perception among women at risk for hereditary breast and ovarian cancer. J Genet Couns 2009; 18:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/26\">",
"      Nee LE. Genetic counseling and presenilin-1 Alzheimer's disease: \"Research Family\" members share some thoughts. Am J Alzheimers Dis Other Demen 2007; 22:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/27\">",
"      Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/28\">",
"      Burt RW, DiSario JA, Cannon-Albright L. Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 1995; 46:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/29\">",
"      Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med 2003; 5:70.",
"     </a>",
"    </li>",
"    <li>",
"     National Society of Genetic Counselors Website. Available at: www.nsgc.org (Accessed on November 16, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/31\">",
"      Metcalfe A, Werrett J, Burgess L, Clifford C. Psychosocial impact of the lack of information given at referral about familial risk for cancer. Psychooncology 2007; 16:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/32\">",
"      Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/33\">",
"      Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/34\">",
"      Burke W, Press N, Pinsky L. BRCA1 and BRCA2: a small part of the puzzle. J Natl Cancer Inst 1999; 91:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/35\">",
"      Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/36\">",
"      Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/37\">",
"      Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/38\">",
"      Fodor FH, Weston A, Bleiweiss IJ, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998; 63:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/39\">",
"      Welch HG, Burke W. Uncertainties in genetic testing for chronic disease. JAMA 1998; 280:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/40\">",
"      Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/41\">",
"      Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005; 129:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/42\">",
"      Cogswell ME, McDonnell SM, Khoury MJ, et al. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med 1998; 129:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/43\">",
"      Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/44\">",
"      Breitner JC, Wyse BW, Anthony JC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 1999; 53:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/45\">",
"      Codori AM, Brandt J. Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet 1994; 54:174.",
"     </a>",
"    </li>",
"    <li>",
"     ACCE: A CDC-sponsored project carried out by the Foundation of Blood Research. Available at: www.cdc.gov/genomics/gtesting/ACCE/acce_proj.htm (Accessed on November 16, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/47\">",
"      Clayton EW. Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003; 349:562.",
"     </a>",
"    </li>",
"    <li>",
"     Weil J. Psychosocial Genetic Counseling, Oxford University Press, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/49\">",
"      Peters JA, Kenen R, Giusti R, et al. Exploratory study of the feasibility and utility of the colored eco-genetic relationship map (CEGRM) in women at high genetic risk of developing breast cancer. Am J Med Genet A 2004; 130A:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/50\">",
"      Marteau TM, Croyle RT. The new genetics. Psychological responses to genetic testing. BMJ 1998; 316:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/51\">",
"      Green RM, Thomas AM. Whose gene is it? A case discussion about familial conflict over genetic testing for breast cancer. J Genet Couns 1997; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/52\">",
"      Rothenberg KH. Genetic information and health insurance: state legislative approaches. J Law Med Ethics 1995; 23:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/53\">",
"      Pokorski RJ. A test for the insurance industry. Nature 1998; 391:835.",
"     </a>",
"    </li>",
"    <li>",
"     Genetic Information Nondiscrimination Act (GINA). Public Law 110-233, 122 Stat. 881 (final passage May 21, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/55\">",
"      Hall MA, Rich SS. Patients' fear of genetic discrimination by health insurers: the impact of legal protections. Genet Med 2000; 2:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/56\">",
"      Patenaude AF, Dorval M, DiGianni LS, et al. Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol 2006; 24:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/57\">",
"      MacDonald DJ, Sarna L, van Servellen G, et al. Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet Med 2007; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/58\">",
"      Godard B, Hurlimann T, Letendre M, et al. Guidelines for disclosing genetic information to family members: from development to use. Fam Cancer 2006; 5:103.",
"     </a>",
"    </li>",
"    <li>",
"     GeneTests: Medical Genetics Information Resource (database online). Available at: www.ncbi.nlm.nih.gov/sites/GeneTests/?db=GeneTests (Accessed on November 09, 2009).",
"    </li>",
"    <li>",
"     US Department of Health, Education, and Welfare. The Institutional Guide to DHEW Policy on Protection of Human Subjects. GPO; US Department of Health, Education, and Welfare, Washington, DC 1971.",
"    </li>",
"    <li>",
"     www.ncbi.nlm.nih.gov/projects/GeneTests/static/concepts/primer/primerordertest.shtml#choosing (Accessed on November 16, 2009).",
"    </li>",
"    <li>",
"     Warby, SC, Graham, RK, Hayden, MR. Huntington Disease. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Available at: www.ncbi.nlm.nih.gov/bookshelf/br.fcgl?book=gene&amp;part=huntington#huntington (Accessed on November 17, 2009).",
"    </li>",
"    <li>",
"     Dietz, HC. (Updated June 30, 2009). Marfan Syndrome. In: GeneReviews at GeneTests: Available at: www.ncbi.nlm.nih.gov/bookshelf/br.fcgl?book=gene&amp;part=marfan#marfan (Accessed on November 17, 2009).",
"    </li>",
"    <li>",
"     Kujovic JL. Factor V Leiden Thrombophilia. In: GeneReviews at GeneTests. Available at: www.ncbi.nlm.nih.gov/bookshelf/br.fcgl?book=gene&amp;part=factor-v-leiden#factor-v-leiden (Accessed on November 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/65\">",
"      Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17:3245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/66\">",
"      Roach JC, Glusman G, Smit AF, et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 2010; 328:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/67\">",
"      Ku CS, Naidoo N, Pawitan Y. Revisiting Mendelian disorders through exome sequencing. Hum Genet 2011; 129:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/68\">",
"      Biesecker LG, Mullikin JC, Facio FM, et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res 2009; 19:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/69\">",
"      Facio FM, Brooks S, Loewenstein J, et al. Motivators for participation in a whole-genome sequencing study: implications for translational genomics research. Eur J Hum Genet 2011; 19:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/70\">",
"      Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature 2009; 461:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/71\">",
"      Heald B, Edelman E, Eng C. Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers. Eur J Hum Genet 2012; 20:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/72\">",
"      Geransar R, Einsiedel E. Evaluating online direct-to-consumer marketing of genetic tests: informed choices or buyers beware? Genet Test 2008; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/73\">",
"      Wasson K. Consumer alert: ethical issues raised by the sale of genetic tests directly to consumers. Am J Bioeth 2008; 8:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/1/24602/abstract/74\">",
"      Levin B, Barthel JS, Burt RW, et al. Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw 2006; 4:384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2901 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24602=[""].join("\n");
var outline_f24_1_24602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ROLE OF THE PRIMARY CARE OR REFERRING CLINICIAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FAMILY HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Collecting the information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - History obtained by a genetic counselor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Interpreting the history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Patterns of inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR GENETIC SERVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Moderate risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      High risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Uncertainty about genetic basis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONTENT OF GENETIC COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Preparation for referral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Where to refer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Information to send with the referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PRINCIPLES OF GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Purpose of genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Penetrance, ascertainment bias, and variable expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Validity and utility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ethical, legal, and psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Genetic discrimination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Disclosure to family members",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Gene test uptake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Whom to test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Informed consent for testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Samples for testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Insurance reimbursement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Where to test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Outcomes of testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Genome screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      MANAGEMENT AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2901\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2901|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/49/25374\" title=\"figure 1\">",
"      4 generation pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/45/10974\" title=\"figure 2\">",
"      Autosomal dominant pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/32/17934\" title=\"figure 3\">",
"      Autosomal recessive pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/46/13038\" title=\"figure 4\">",
"      X linked recessive pedigree",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2901|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/6/24685\" title=\"table 1\">",
"      Genetic terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/40/7820\" title=\"table 2\">",
"      Collecting family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/57/8091\" title=\"table 3\">",
"      Risks for common diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/24/36235\" title=\"table 4\">",
"      GENES mnemonic for identifying hereditary conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/15/3326\" title=\"table 5\">",
"      Review genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/19/40252\" title=\"table 6\">",
"      Methods of genetic testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=related_link\">",
"      Basic principles of genetic counseling for the obstetrical provider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=related_link\">",
"      Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=related_link\">",
"      Overview of Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=related_link\">",
"      Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=related_link\">",
"      Primary prevention of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2872?source=related_link\">",
"      Risk prediction models for breast cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_1_24603="Contraceptive counseling";
var content_f24_1_24603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraceptive counseling tool: the top 10 questions that facilitate contraceptive counseling",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. What are your contraceptive goals? Do you ever plan to get pregnant? When?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Are you currently having sex with a male partner?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Have you tried any contraceptive methods? If so, which one(s)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. What did you like/dislike about the method(s)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Are you a good pill taker?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. For user-controlled methods, how often did you forget to use the method?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Are there any methods you have heard about and would like to try?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. How important is spontaneity of use?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Is protection from sexually transmitted infections important considering your life situation?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Is cost an issue? Does your health insurance plan cover any contraceptive method?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Association of Reproductive Health Professionals. Clinical Proceedings: Periodic Well-Woman Visit: Individualized Contraceptive Care. Washington, DC; April 2004. Copyright &copy; Association of Reproductive Health Professionals (ARHP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24603=[""].join("\n");
var outline_f24_1_24603=null;
var title_f24_1_24604="Monitoring of FTM transsexual persons on cross-hormone therapy";
var content_f24_1_24604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monitoring of female-to-male transsexual persons on cross-hormone therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Evaluate patient every 2-3 months in the first year and then 1-2 times per year to monitor for appropriate signs of virilization and for development of adverse reactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        2. Measure serum testosterone every 2-3 months until levels are in the normal physiological male range:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. If the level is &gt;700 ng/dL or &lt;350 ng/dL, adjust dose accordingly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. For parenteral testosterone undecanoate, testosterone should be measured just before the next injection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. For transdermal testosterone, the testosterone level can be measured at any time after 1 wk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        d. For oral testosterone undecanoate, the testosterone level should be measured 3-5 h after ingestion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        e. Note: During the first 3-9 months of testosterone treatment, total testosterone levels may be high, although free testosterone levels are normal, due to high SHBG levels in some biological women.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Measure estradiol levels during the first 6 months of testosterone treatment or until there has been no uterine bleeding for 6 months. Estradiol levels should be &lt;50 pg/mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Measure complete blood count and liver function tests at baseline and every 3 months for the first year and then 1-2 times a year. Monitor weight, blood pressure, lipids, fasting blood sugar (if family history of diabetes), and hemoglobin A1c (if diabetic) at regular visits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Consider BMD testing at baseline if risk factors for osteoporotic fracture are present (eg, previous fracture, family history, glucocorticoid use, prolonged hypogonadism). In individuals at low risk, screening for osteoporosis should be conducted at age 60 and in those who are not compliant with hormone therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. If cervical tissue is present, an annual pap smear is recommended by the American College of Obstetricians and Gynecologists.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BMD: bone mineral density.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132. Copyright &copy; 2009 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24604=[""].join("\n");
var outline_f24_1_24604=null;
var title_f24_1_24605="Less common causes of FUO";
var content_f24_1_24605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Less common diagnoses of fever of unknown origin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amebic liver abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brucellosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic active hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dental abscesses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diskitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epididymitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fascioloiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gonococcal arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex encephalitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infectious mononeucleosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kala azar",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kikuchi's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prostatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyelonephritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyometria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatic fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sinusitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Typhoid fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Whipple's disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Malignancies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrial myxoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aleukemic leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colon carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kaposi's sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lung cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple myeloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Systemic diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Allergic granulomatous angiitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antiphospholipid syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Granulomatous hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypersensitivity vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Panaortitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reiters syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Behcet's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic fatigue syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disorders of temperature regulation (neurologic and dermatologic)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Environmental (metal and polymer fume fevers)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Factitious fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mediterranean fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuroleptic malignant syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Periodic fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary emboli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retroperitoneal hematomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyroiditis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24605=[""].join("\n");
var outline_f24_1_24605=null;
var title_f24_1_24606="Mortality after thrombolysis based on TIMI flow";
var content_f24_1_24606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75629%7ECARD%2F70952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75629%7ECARD%2F70952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    TIMI grade 3 coronary flow is associated with improved survival after thrombolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the GUSTO-I trial, the 30-day mortality rate after thrombolysis for acute ST elevation myocardial infarction varied with the degree of vessel patency achieved. The mortality was lowest (4.3 percent) in patients with TIMI grade 3 (normal) flow in the infarct-related artery at 90 minutes. Partial restoration of flow (TIMI grade 2) did not improve outcomes compared to no or or faint flow (TIMI grade 0 or 1).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The GUSTO Investigators. N Engl J Med 1993; 329:673.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival after thrombolytic therapy is better with TIMI grade 3 flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among all patients with acute ST elevation myocardial infarction entered into the GUSTO-I trial, those with TIMI grade 3 (normal) flow in the infarct-related artery at 90 minutes after thrombolytic therapy had a significantly higher rate of two-year survival than patients with TIMI grades 0, 1, or 2. Partial restoration of flow (TIMI grade 2) did not improve outcomes compared to no or or faint flow (TIMI grade 0 or 1). A similar relationship was seen when the analysis was limited to patients who were alive at 30 days after the infarction (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ross AM, Coyne KS, Moreyra E, et al, for the GUSTO-I Angiography Investigators. Circulation 1998; 97:1549.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24606=[""].join("\n");
var outline_f24_1_24606=null;
var title_f24_1_24607="Uncircumcised penis";
var content_f24_1_24607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uncircumcised penis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_1_24607=[""].join("\n");
var outline_f24_1_24607=null;
